Platform data discovery EMIF Data Catalogue textbook example EMIFs mission improve identification access assessment reuse health data within European Union Toggle navigation EMIF CATALOGUE Access EMIF Catalogue via information project lifetime European Medical Information Framework EMIF ha developed made EMIF Data Catalogue publicly available research community EMIF Data Catalogue textbook example EMIFs mission improve identification access assessment reuse health data within European Union EMIF Catalogue allows user explore populationbased eg Electronic Health Record EHRderived Regional databases etc cohortderived predominately within Alzheimers Disease data source consented provide information purpose bona fide researcher wanting explore potential data partner studies June   populationbased  cohortbased data partner contained within Catalogue across  country collaborating within EMIF currently  unique user Catalogue home  different community far eg EPAD MOCHA ADVANCE  latter clearly indicates tremendous need EMIF Catalogue Catalogue initially offered highlevel meta data information data source additional tool developed installed allow data source suitability evaluation initiate new research study data source secure environment would welcome enquiry related Catalogue indeed feedback user following access approval questions feedback via within Catalogue Access Catalogue via following steps Please access Catalogue  accessing Catalogue login frontend page please click Create Account follow instruction provided Sign In Following Sign In user able access EHRderived andor cohortderived community pending approval Community Manager User support via lefthand navigation panel inclusive help function behalf EMIF hope EMIF Catalogue significant asset EU research community look forward continued development use eventually within broader research platform communities content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation HOME Welcome website European Medical Information Framework EMIF project EMIF wa publicprivate consortium  partner ran  years ending June  time span EMIF ha successfully improved access human health data via providing tool workflow discover assess access reuse human health data Access EMIF Data Catalogue EMIF Platform EHR Video animation provides overview service approach IMI project EHRderived population data Published   EMIF Platform Cohort Data Video video provides overview service approach IMI project cohortderived data Published   content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation combination rapidly increasing medical knowledge advance information technology allowing researcher use human health data way previously unimaginable Increasingly challenge find sufficient data fuel research time huge volume suitable data already collected stored electronically routine Electronic Healthcare Record EHR databases researchdriven cohort study associated biobanks sources However data exists disparate location systems generally used isolation rarely aggregated larger datasets meaning full potential realised Additionally privacy legal ethical issue related data use also need properly addressed EMIF Introductory Video animation provides brief introduction EMIF project key goal help improve access patientlevel data European Medical Information Framework EMIF wa launched January  EMIF project fiveyear project time itwill develop common technical governance solution improve access use health data aim common Information Framework  link facilitate access diverse medical research data sources ensure immediate applicability EMIF project includes two specific therapeutic research topic help guide development Information Framework onset Alzheimers disease  metabolic complication obesity  EMIF receives support Innovative Medicines Initiative Joint Undertaking IMIJU grant agreement n  resource composed financial contribution European Unions Seventh Framework Programme FP European Federation Pharmaceutical Industries Associations EFPIA kind contribution Links relevant project The EHRCR project one largest publicprivate partnership aiming providing adaptable reusable scalable solution tools services reusing data Electronic Health Record system Clinical Research Electronic Health Record EHR data offer large opportunity advancement medical research improvement healthcare enhancement patient safety aims show robust new method RWE collection synthesis could adopted earlier pharmaceutical RD healthcare decision making process IHDThe vision ofiHD become European organization reference guiding catalyzing best efficient trustworthy us health data interoperability optimizing health knowledge discovery The EPAD project part global effort fight Alzheimers disease major European initiative create novel environment testing numerous intervention targeted prevention Alzheimers dementia Dementias PlatformUK aUK powerhouse dementia research designed tofasttrack scientific understanding treatment prevention disease EMIF Brochure available downloading PDF version EMIF Brochure providing overview main achievement date content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation EMIFPLATFORM EMIF Platform EMIFPlatform Project Overview EMIF ha ultimately build integrated efficient Information Framework consistent reuse exploitation available patientlevel data support novel research supportdata discoverydata evaluationand thenreuse EMIFPlatform System Overview EMIFPlatform ha developed platform allowing access multiple diverse data sources EMIFPlatform made data available browsing allows exploitation multiple way end user EMIFPlatform ha leveraged data  Million European adult child mean federation healthcare database cohort  different country DKIT NL UK ES EE designed representative different type existing data source populationbased registries hospitalbased databases cohorts national registries biobanks etc EMIF Data Catalogue available outside EMIF bona fide researcher information via  EMIF Platform EHR Video video provides overview service approach via EHR data postIMI EMIF Platform Cohort Video video provides overview service approach via Cohort data postIMI EMIFPlatform Objectives achieve EMIFPlatform objectives project wa divided eight work package WPWP below addition explore EMIFPlatform Work Packages WP Use sustainability models community building  outreach WP Use sustainability models community building  outreach WP Architecture solution development security  privacy technology WP Analysis processing  visualization method tool WP Data extraction benchmarking aggregation  linkage WP Harmonization  Semantics WP Governance WP Framework Requirements Evaluation EMIFPlatform Achievements Tool Development Key tool developed data shop window support platform architecture also utilised initiative ADVACE MOCHA IMIEPAD DPUK Development  integration TASKA EMIF catalogue manage workflow Common Data Model EMIF OMOPCDM OHDSI Mapped  European Databases OMOPCDM Contributes extension CDM Standardized Vocabularies accommodate European data Supports European OHDSI initiative stimulate adoption CDM collaboration across Europe Atlas ATLAS tool developed OHDSI used conduct scientific analysis standardized health data EMIF evaluating OHDSI tool EMIF community actively contributing development Biomarker Discovery Raw cohort data integration analysis via tranSMART allied bioinformatics tooling development support biomarker discovery AD metabolic disorder  subject  AD cohort harmonized Support multiomics data analysis EMIFPlatform Tools Workflow Management Workflow Management Private Remote Research Environment PRRE Private Remote Research Environment PRRE Variable Selection Tool VST Variable Selection Tool VST ParticipantSelection Tool PST ParticipantSelection Tool PST CohortSelection Tool CST Catalogue CohortSelection Tool CST Catalogue Switchbox Switchbox Private Remote Research Environment PRRE Private Remote Research Environment PRRE Workflow Management Workflow Management OMOP CDMOHDSI Tools OMOP CDMOHDSI Tools EMIFCatalogue EMIFCatalogue Data extractiontooling Data extractiontooling Ethical Code Practice ECoP Ethical Code Practice ECoP EMIFPlatform Tools Governance  SecurityIntegration Layer Cohort architecture support EMIFAD data discovery  reuse workflow EHR architecture support generic data discovery  reuse workflow Datareuse Dataaccess Dataassessment Datadiscovery Datareuse Dataaccess Dataassessment Datadiscovery EMIFPlatform Tools Governance  SecurityIntegration Layer Cohort architecture support EMIFAD data discovery  reuse workflow EHR architecture support generic data discovery  reuse workflow Datareuse Dataaccess Dataassessment Datadiscovery Datareuse Dataaccess Dataassessment Datadiscovery WP  Framework requirement  evaluation Carlos Daz Synapse Peter Egger GSK Synapse COLEAD GSK COLEAD EMC Janssen UCL PENTA EMBL EUROREC UAVR ULEIC UPF APHP ARS STIZON AUH GENOMEDICS BIPS PEDIANET UTARTU UNIMAN BF CUSTODIX Pfizer SERVIER Amgen UCB MERCK IDIAP JORDI GOL GOALS  OBJECTIVES objective are continuously elucidate user requirement evaluate EMIFPlatform progressively developed deployed cycle work plan ensure adequate input prospective users especially present future research projects input EFPIA participants important future user platform cycle work plan evaluate user perspective result cycle feeding back development work packages WP  Governance federation DB fingerprinting legal context  ethic Nigel Hughes Janssen  TBD EMC EMC COLEAD JANSSEN COLEAD SYNAPSE UCL PENTA EMBL EUROREC UPF ARS STIZON AUH GENOMEDICS BIPS PEDIANET UTARTU UNIMAN BF GSK SERVIER BI Amgen AE IDIAP Jordi Gol GOALS  OBJECTIVES objective to Provide detailed information the fingerprint participating database respect population included database data available database local data model mechanism generating data ability address specific reuse issue such ability contact GP patients inclusion patient clinical trials Specify procedure followed governance federation including required safeguard criterion admission Define different type user EMIFPlatform level access type user procedure safeguard handle permissions Ensure project followsethicalprinciples conforms relevant international national regulation regard WP  Harmonization  semantics Dipak Kalra UCL Michel Van Speybroeck Janssen UCL COLEAD JANSSEN COLEAD EMC UPF APHP ARS STIZON AUH GENOMEDICS BIPS PEDIANET UTARTU UNIMAN BF GSK SERVIER ROCHE IDIAP Jordi Gol GOALS  OBJECTIVES objective are analyse harmonisation semantic needs devise common framework reference guide interoperability work project including metadata develop common data model used throughout EMIFPlatform architecture represent query result set aggregate patientlevel data design implement service support specific crossmappings terminology used clinicalmedical terms medicinal product unit measurement WP  Data extraction benchmarking aggregation  linkage Peter Rijnbeek EMC Martijn Schuemie Janssen EMC COLEAD JANSSEN COLEAD UCL UPF ARS STIZON AUH GENOMEDICS PEDIANET UTARTU UNIMAN BF CUSTODIX GSK SERVIER BI Amgen ROCHE IDIAP Jordi Gol GOALS  OBJECTIVES objective are develop common framework extracting data across different data sources benchmark result extraction across different data source explicit objective account difference observed provide tool linking data different source allow individual tracked data sources taking account transition childhood adulthood aggregate data order comply privacy governance rule control reuse data WP  Analysis processing  visualization method tool Alvis Brazma EMBL Rudi Verbeeck Janssen EMBL COLEAD Janssen COLEAD EMC UCL UAVR ULEIC UPF UTARTU UNIMAN GSK SERVIER PFIZER GOALS  OBJECTIVES objective are develop dedicated data analysis algorithm tool help exploitation data made available platfom leveraging reusing possible already existing tools develop visualisation tool EHR based generalisation concept genome browser distributed annotation systems develop specific analysis tool broad translational research datasets used vertical project apply data analysis problem arising context projects WP  Architecture solution development security  privacy technology Jos Luis Oliveira UAVR Philippe Baudoux UCB UAVR COLEAD UCB COLEAD EMC Synapse UCL EMBL EUROREC ULEIC UPF PEDIANET UNIMAN CUSTODIX Janssen SERVIER Amgen GOALS  OBJECTIVES objective are engineer ICT infrastructure federation resources including dynamic support common data model variable operation procedures provide technical infrastructure secure crossproject data exchange create development environment EMIFPlatform ecosystem enabling creation software clinical information browser evolving biomedical knowledge base Private Remote Research Environments WP  Use sustainability models community building  outreach Eva Molero Synapse Bart Vannieuwenhuyse Janssen Synapse COLEAD Janssen COLEAD EMC UCL PENTA EMBL EUROREC UAVR ULEIC UPF APHP ARS STIZON AUH GENOMEDICS BIPS PEDIANET UTARTU UNIMAN BF CUSTODIX GSK SERVIER Amgen ROCHE IDIAP Jordi Gol GOALS  OBJECTIVES objective are analyze need different key stakeholder potential user platform aim develop sustainability model business model serf need acceptable data custodian develop test different sustainability model derived analysis above ensure longterm maintenance operation information framework developed project Outreach WP also aim connecting EMIF relevant project IMI other ha ambition identify connect new data source network WP  Use sustainability models community building  outreach Carlos Daz Synapse Bart Vannieuwenhuyse Janssen EMIF partner GOALS  OBJECTIVES objective are overall objective WP ensure successful implementation project scientific financial management level achieve focus  main area  Ensure efficient management scientific activity financial allocationreporting organisation project meeting Ensure effective communication partner support sharing best practice maximise synergy prevent duplication Designing implementing dissemination plan communication strategy Managing Intellectual Property right deriving value foreground information generated Ensure appropriate risk management particularly joint risk across whole programme interface three topic EMIF Code Practice ECoP EMIF platform used for assessing feasibility study conducting research bonafide research organisation objective discovering new knowledge intended public good made publicly accessible ie published ECoP wa developed order help ensure that EMIF Platform Services used way comply legislation  European GDPR policy data protection EMIF upholds best practice protection personal privacy information governance EMIF promotes best practice conduct clinical research using health data public good Data source Data user always autonomy data made accessible type research must adhere ethical rule privacy protection policy data source always determine ethical acceptability scientific validity may use data specific agreed research purpose must transparent data must acknowledge source data used EMIF EMIF Catalogue key idea EMIF Catalogue allow researcher find specific database aligned research purposes providing summarized overview number geographically scattered healthcare databases accomplish this EMIF Catalogue flexible web system supported Community concept ie group joining database user clinical interests Features Communitybased access management Database fingerprinting Free text advanced search Suitability assessment through Jerboa Achilles Distributed management group data RoleBased access control RBAC Open architecture pluginbased TASKA TASKA innovative platform designed streamline creation modular easily extendable workflow manage data extraction handling general work processes based SoftwareasaService approach making versatile easy integrate third party applications platform allows several user collaborate interact creation execution distributed workflows relying easytouse interface managing complex procedures Features Easytouse visual editor Task definition inputs outputs dependency Questionnaire task Workflow scheme templates Running study workflows Task assignment notification Web service allow system operate without interface Jerboa Reloaded Work package  Data extraction benchmarking aggregation  linkage mainly involved important challenging task develop complex scenario informed consent cannot obtained example case electronic healthcare record EHR collected general practitioners access patent data often restricted anonymized aggregated data Jerboa Reloaded extraction tool developed EMIF project support data extraction processing EHR databases used socalled distributed network design ie run deidentification linkage analysis aggregation locally data source site Jerboa run script contains parameter specific study design ha advantage local analysis performed common standard way subject small difference implementation local statisticians studyonly data necessary particular study shared analytical dataset OCTOPUS Private Remote Research Environment OCTOPUS infrastructure used prototype private remote research environment PRRE WP allows secured file transfer data custodian used collaborate aggregated data generated Jerboa Reloaded OCTOPUS remote research environment sociotechnological framework ha developed Erasmus MC past ha already proven value various projects stimulates geographically dispersed research group collaborate ha resulted consortium engaged phase drug safety research achieve successful sustainable collaboration database custodian data suppliers custodian reside research institutes analytical task distributed well main purpose OCTOPUS stimulate collaborative drug safety research secured environment EMIF dedicated PRRE currently developed scalable optimized based experience OCTOPUS Participant Selection Tool Participant Selection Tool allows researcher get overview patient profile given cohort filtering set predefined key characteristics tool ha currently built provide capability AD cohort data sets user interface designed minimise learning curve Federated data source represented single tabular graphical view Filtering categorical date continuous key variable possible result count number matching patient across different cohorts basis tool Knowledge Object knowledge object ontology different data source in case cohort data mapped use semantic technology offer required flexibility ontology develops additional data source added tool accommodate different project eg single data source participating one projects additional characteristic added given project framework also used develop additional tools ultimately enabling integrated data pipeline cohort data Virtual Selection Tool VST VST provides researcher overview available variable counts values followed data access request selected cohort owners TranSMART TranSMART knowledge management application built open source component investigate correlation genetic phenotypic clinical data aid predictive biomarker discovery consists webbased graphical data mining application connects server based data warehouse TranSMART wa made open source  tranSMART Foundation wa established  provide governance coordination new developments Important contribution come IMI eTRIKS CTMM TraIT Pfizer Sanofi Janssen amongst others TranSMART combine clinical high dimensional data gene expression single nucleotide polymorphisms SNPs Rulesbased medicine RBM genomewide association study GWAS copy number variation CNV etc EMIF main emphasis ha harmonized clinical data High dimensional data expected eg EMIFAD  sample cohort TranSMART allows easy generation query phenotypes genotypes combination Study group formed ad hoc generate summary statistic hypothesis testing Several advanced analysis pipeline built in boxplots ANOVA scatterplots linear regression KaplanMeier plot survival analysis etc GenePattern functionality available gene expression proteomic analysis Subjects individual cohort pooled virtual cross trial cohort unified data analysis Multiomics Research Environment MORE Cloud computing provides user number benefits reduction computational costs universal access date software choice applications flexibility many cloud platform Research project choose from Amazon Web Services OpenStack VMWare Google Cloud etc transferrable solution different cloud platform ha specialised component clinical omics data analysis addition implies flexible architecture allows adding new tool pipeline upon request following pipeline tool currently available version  tranSMART clinical data analysis R Cloud R parallel computing R specific analysis iRAP pipeline adapted Docker cluster analyse transcriptomics sequencing data NGSeasy pipeline adapted Docker cluster analyse genomics sequencing data MZmine adapted Docker cluster analyse proteomics metabolomics LCMS data Sequence Imp pipeline adapted Docker cluster analyse microRNA sequencing data tranSMART Docker cluster R Cloud connected use shared file system Docker cluster R Cloud benefit scalability cluster computing usage multiple VMs job queue task scheduler New resource added needed opensource project code publicly available at  EMIF instance available EMBLEBI Embassy Cloud accessible upon request EMIF users instance used EMIFAD biomarker discovery Knowledge Object Framework Michel van Speybroeck James Cunningham et al Janssen  UNIMAN knowledge object framework consists number component support harmonization effort clinical data knowledge object semantic representation clinical variable contains descriptive metadata executable rule specify relation mapping knowledge objects actual data local knowledge object representation source variable contains raw data global knowledge object defines harmonized cross trial variable serf mapping target local knowledge objects Several level derived knowledge object possible thus creating dependency graph main goal knowledge object make data harmonization process efficient specifying minimal information understand clinical measurement mapping harmonized variable information owned maintained local data source research community specifying metadata mapping rule using semantic web technology reasoner used perform actual data extraction harmonization Security restriction also defined local variable automatically propagated global knowledge objects knowledge object framework consists following technical components central knowledge object library contains definition core classes property global knowledge objects local ontology data source developed using tool Protg for definition local concepts Pentaho for specifying mapping rule connection local data sources Executing mapping rule result local dataset harmonized global standard stored Stardog triple store Stardog sparql API make data available federated query outflow tool Participant selection Tool Variable Selection Tool OMOP CDMOHDSI Tools OHDSI tool eg ACHILLES provides researcher overview patient profile given cohort filtering limited set preagreed characteristics Mapped  European Databases OMOPCDM Contributes extension CDM Standardized Vocabularies accommodate European data Supports European OHDSI initiative stimulate adoption CDM collaboration across Europe Atlas ATLAS tool developed OHDSI used conduct scientific analysis standardized health data EMIF evaluating OHDSI tool EMIF community actively contributing development Workflow Management Workflow management ensures integrity process researcher data sources management task process steps Workflow Managment Workflow management ensures integrity process researcher data sources management task process steps Switchbox Switchbox provides single interface cohort owners multiple harmonised output tools Corhort Selection Tool CST CST provides researcher overview potential cohort data availability suitability content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation EMIFAD EMIFAD Project Background multiple clinical trial dementia failing past years attention ha recently shifted subject Alzheimers disease AD reached stage dementia yet ie predementia Since subject limited brain damage suggested likely responsive treatment subject fullblown dementia important target group future treatment studies EMIFAD Project Objectives Trial design predementia AD however challenging subject predementia AD difficult identify limited information available outcome lack reliable diagnostic prognostic marker predementia AD explained availability smallscale ongoing biomarker study longitudinal cohort including subjects EMIF ha linked information unlocked true potential studies connecting relevant cohort study across Europe EMIFAD ha set panEuropean platform largescale research biomarkers risk factor neurodegenerative disorders biomarker discovery activity EMIFAD driven extreme phenotype approach decline biomarker status wa used end point biomarker discovery rather clinical diagnosis so EMIFAD ha developed new treatment targets multimodalityomics diagnostic tool qualification level biomarker datasets suitable presentation regulatory authority prior approval use clinical trial practice Finally prediction rule cognitive decline presymptomatic prodromal AD developed improve clinical diagnosis prognosis equally support subject selection stratification future clinical trials achievement possible EMIFAD combined largescale patient cohorts linkage EHR data cutting edge biomarker discovery expertise Work Packages Overview Identify predictor Alzheimers Disease AD preclinical prodromal phase Work Packages WP EMIFAD Validate new biomarkers andselect subject prevention trial WP Biomarker discovery withextreme phenotype endpoint WP Characterise study populationand define extreme phenotype WP Define study population data collection WP EMIFAD Project Achievements EMIF AD Catalogue Tools developed support data suitability via cohort selection patient profile selection research query userfriendly EMIF Catalogue publicly available search AD cohort interest Availability European AD cohort information one place facilitate future research collaboration Several initiatives IMIEPAD DPUK IMIPRISM JPNDEADB INTERDEM already taken EMIF Catalogue EMIFAD Multimodal Biomarker Discovery study Project lead Pieter Jelle Visser VUmc Amsterdam  Maastricht University Simon Lovestone Oxford University  Janssen Pharmaceutica Johannes Streffer UCB  University Antwerpen Coordinator data management Isabelle Bos VUmc Amsterdam  Maastricht University isabellebosmaastrichtuniversitynl Aim  design main aim EMIFAD Multimodal Biomarker Discovery EMIFAD MBD study wa accelerate discovery novel diagnostic prognostic biomarker AD unravel underlying pathophysiological mechanism using existing data samples harmonized pooled clinical data  cohort study across Europe sample cerebrospinal fluid plasma DNA MRI scan centrally analyzed using different omics technique proteomics metabolomics genomics total material  participant wa included n control n MCI n AD dementia Figure  provides schematic overview EMIFAD MBD study data generated context EMIFAD MBD study available upon request approval research question parent cohort EMIFAD team Data request submitted via EMIFAD Catalogue  Scientific output Bos I Vos SJ Vandenberghe R Scheltens P Engelborghs S Frisoni G Visser PJ  EMIFAD Multimodal Biomarker Discovery Study Design method cohort characteristics Alzheimer Research  Therapy Kate ten M Redolfi A Bos I Vos SJB Vandenberghe R Gabel S Barkhof F  MRI predictor amyloid pathology result EMIFAD Multimodal Biomarker Discovery study Alzheimer Research  Therapy Morgan A R Touchard S Leckey C OHagan C NevadoHolgado A J Barkhof F  Engelborghs S  Inflammatory biomarkers Alzheimers disease plasma Alzheimers  dementia Kim M Snowden S Suvitaival T Ali A Merkler D J Ahmad T  Hye A  Primary fatty amide plasma associated brain amyloid burden hippocampal volume memory European Medical Information Framework Alzheimers Disease biomarker discovery cohort Alzheimers  dementia   Bos I Vos S Verhey F Scheltens P Teunissen C Engelborghs S  Bordet R  Cerebrospinal fluid biomarkers neurodegeneration synaptic integrity astroglial activation across clinical Alzheimers disease spectrum Alzheimers  dementia   EMIFAD  study Project lead Pieter Jelle Visser VUmc Amsterdam  Maastricht University Stephan Carter University Manchester Coordinator data management Nienke Legdeur  Rene Haan VUmc Amsterdam rhaanamsterdamumcnl Aim  design EMIFAD  study aimed identify factor associated resilience cognitive impairment oldestold study wa conducted Amsterdam University Medical Center University Manchester baseline neuropsychological clinical data vascular comorbidities mood sleep physical performance genetic factors collected  participant n normal cognition n cognitive deficits Regarding imaging measures baseline MRI n AmyloidPET n MEG n collected addition skin biopsy n ultrasound carotid artery n Currently Oct  first annual followup measurement completed n November  plan second annual followup  Data request submitted via EMIFAD Catalogue  Scientific output Legdeur N Tijms BM Konijnenberg E den Braber A ten Kate M Sudre CH Visser PJ Associations Brain Pathology Cognitive Physical Markers Age Cognitively Normal Individuals Aged  Years Journals Gerontology Series A Legdeur N Badissi M Carter SF de Crom S van de Kreeke A Vreeswijk R  Visser PJ Resilience cognitive impairment oldestold design EMIFAD  study BMC Geriatr EMIF PreclinAD study Project lead Pieter Jelle Visser VUmc Amsterdam  Maastricht University Stephan Carter University Manchester Coordinator data management Jori Tomassen VUmc Amsterdam jtomassenamsterdamumcnl Aim  design main aim EMIFAD PreclinAD study wa indentify new risk factor diagnostic marker amyloid pathology cognitive decline cognitively normal subject without amyloid pathology investigate monozygotic twin pair included genetic environmental pathway identified baseline measurement n cognitively healthy elderly monozygotic twin aged  year older included Manchester Newcastle Age Cognitive Performance Research Cohort Netherlands Twin Register baseline following measurement done neuropsychological examination n blood sampling n CSF collection n ultrasound carotid artery n magnetoencephalography n collection ophthalmological marker n n  following followup measure done two years containing neuropsychological examination n blood collection n CSF sampling n second followup conducted  Data request submitted via EMIFAD Catalogue  Scientific output Konijnenberg E Carter SF Ten Kate M den Braber A Tomassen J Amadi C  Visser PJ EMIFAD PreclinAD study study design baseline cohort overview Alzheimers Res Ther  Aug  doi s Konijnenberg E den Braber A ten Kate M Tomassen J Mulder SD Yaqub M   Visser PJ Association amyloid pathology memory performance cognitive complaint cognitively normal older adults monozygotic twin study Neurobiology Aging  May   WP  Definition study population data requirement data collection Pieter Jelle Visser UM Michael Arrighi Janssen UM COLEAD JANSSEN COLEAD UNIMAN VUMC IRCCFSFBF MAAT CAMCOG BI PFIZER ROCHE GOALS  OBJECTIVES main objective is overall aim WP collect data required development validation new biomarkers predementia AD overarching EMIF data collected used analysis WP  WP  subobjectives are select cohort used biomarker discovery validation pool data cohort study Private Remote Research Environment link data research cohort EHR collect additional data key AD biomarkers cognitive marker subject ongoing longitudinal cohort study WP  Definition study population data requirement data collection Pieter Jelle Visser UM Michael Arrighi Janssen UM COLEAD JANSSEN COLEAD UNIMAN VUMC IRCCFSFBF MAAT CAMCOG BI PFIZER ROCHE GOALS  OBJECTIVES main objective is overall aim WP collect data required development validation new biomarkers predementia AD overarching EMIF data collected used analysis WP  WP  subobjectives are select cohort used biomarker discovery validation pool data cohort study Private Remote Research Environment link data research cohort EHR collect additional data key AD biomarkers cognitive marker subject ongoing longitudinal cohort study WP  Characterisation study population definition extreme phenotype M Gordon BI G Novak Janssen Engelborghs UA B Dubois UPMC BI Janssen UA UPMC VTT VUmc Maastricht UM GSK Pfizer Roche CamCog Newcastle KCL Oxford GOALS  OBJECTIVES main objective are characterize study population define extreme phenotype based subject selected WP  subobjectives are provide summary statistic cohort selected WP  operationalize criterion presymptomatic AD prodromal AD define extreme phenotype based rate decline develop multivariate prediction model cognitive decline define extreme phenotype based AD biomarkers define extreme phenotype based resilience dementia old age WP  Biomarker Discovery Simon Lovestone UOXF Johannes Streffer Janssen UOXF COLEAD Janssen COLEAD KCL VUmc UGOT KI VTT IRCCSFBF PSPLC VIB MAAT UZL GSK PFIZER BI ROCHE GOALS  OBJECTIVES main objective is objective WP discover new biomarkers genetic marker diagnosis prognosis predementia AD using extreme phenotype defined WP  subobjectives are perform proteomics CSF plasma perform GWAS analyses exome sequencing assessment epigenomic profiles transcriptome profiling perform metabolomics CSF plasma perform voxel based MRI analysis develop multivariate class prediction algorithm generate assay new biomarkers WP  Validation new biomarkers identification selection individual pharmacological intervention Hilkka Soininen UEF Piotr Lewczuk UKER Henrik Zetterberg UGOT TBD Janssen UEF COLEAD Janssen COLEAD VUmc UGOT IRCCSFBF UKER MAAT UZL GSK BI GOALS  OBJECTIVES main objective is main objective WP crossvalidate biomarkers discovered WP  independent sample develop recruitment strategy AD prevention trials subobjectives are crossvalidate new plasma CSF genetic MRI marker WP  independent cohort investigate relation genetic risk factor amyloid pathology neuropathological examination investigate relation new AD plasma marker longterm cognitive decline general population develop stepwise screening algorithm recruitment subject presymptomatic AD prodromal AD analyse data ongoing prodromal AD trial select site selection inclusion subject predementia AD trial content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation EMIFMETABOLIC EMIFMetabolic Project background Accumulating evidence indicates obesity closely associated increased risk metabolic complication type  diabetes coronary heart disease nonalcoholic fatty liver disease cancers However association obesity complication complex high interindividual variability susceptibility specific metabolic complication obesity association expected additionally influenced different constitutional environmental obesityspecific factors thus complicating development adequate treatments EMIFMetabolic Project Objectives EMIFMetabolic focus two distinct pathway individual obese may vary risk complication obesity One identify genetic cause obesity relation metabolic complication obesity pathway characterize individual identify marker associated metabolic risk irrespective degree obesity based knowledge many obese individual become dysmetabolic insulin resistant instance complementary approach studying extreme phenotype populationbased cohort followed discovery predictor metabolic complication adult paediatric obesity ha lead innovative diagnostic tests paved way novel therapeutic targeted highrisk individuals provided infrastructure select individual targeted pharmacological intervention genetic epigenetic omics platforms Identified novel mechanism potential target therapy characterized appropriate cell animalbased model facilitate transition human studies end EMIFMetabolic ha brought together top European expert genetics epidemiology genomics omic technologies human murine physiology system approach stateoftheart technologies Work Packages Overview EMIFMET Identify predictor metabolic complication obesity EMIFMET Work Packages WP Evaluate epidemiology obesityrelated clinical condition large realworld database WP Validate sensitivityspecificity novel biomarkers vs currently available biomarkers WP Characterise heterogeneity metabolic consequence obesity small medium large clinical population outcome data WP Identify novel biomarkers mechanism obesityassociated complication using extreme phenotype unbiased omics technologies well targeted approach WP EMIFMetabolic Project Achievements Cohort Development Molecules related insulin secretion capacity insulin resistance NAFLD identified omics biomarker discovery programme currently undergoing validation sample set  individual Discovery Potential new therapeutic target NAFLDNASH investigation Platform database largest BMI cohort identified primary care patient WP  Use carefully characterized extreme phenotype identify biomarkers metabolic risk Peter Arner KI Markku Laakso UEF Dawn Waterworth GSK KI COLEAD UEF COLEAD GSK COLEAD UGOT UCAM UH INSERM ULEI UGLA VKJK Janssen PFIZER NOVO Amgen BI GOALS  OBJECTIVES main objective is characterize detail using omics technology extreme phenotype related complication obesity including insulin resistance liver fat first degree relative diabetics Response weight loss also characterized interesting biomarkers subsequently evaluated tissue culture animal model taken forward validation medium sized cohort WP interesting marker correlated endpoint interest property would lend clinically useful robustness variability frequency tissue specificity ease detection subobjectives are Detailed omics analysis well characterized sample extreme phenotype dietary intervention Comprehensive integrated analysis detailed omics data using data reductionminingstatistical technique inform marker selection Experimental assessment selected biomarkers cellbased animal model ass validity drug target diagnostic tools WP  investigation heterogeneity metabolic consequence obesity mediumsized well phenotyped cohort study Nick Wareham UCAM Dawn Waterworth GSK Julia Brosnan PFIZER UCAM COLEAD GSK COLEAD PFIZER COLEAD UGOT UH UEF INIPI VKJK ULEI Janssen Amgen BI GOALS  OBJECTIVES main objective is use candidate discovery approach identify biomarkers associated metabolic consequence obesity investigate causal significance mediumsized well phenotyped cohort largescale nested casecohort studies subobjectives are select quantitative metabolic cohort study test biomarkers prediction metabolic consequence obesity use candidate discovery approach identify potential biomarkers study association likelihood causality biomarkers prediction metabolic consequence obesity WP  Validate novel risk factor general population adult child Naveed Sattar UGLA Katrina Loomis PFIZER UGLA COLEADPFIZER COLEAD UGOTUCPH Janssen GSK ROCHE Amgen BI GOALS  OBJECTIVES main objective is overall objective WP measure test ability new metabolic biomarkers predict obesityrelated outcome using retrospective prospective studies subobjectives are Identify cohort EHR available baseline serum  plasma samples acceptable phenotyping ie conventional vascular risk factors family history data level BMI waist circumference access outcome vascular disease ie CHD events incident diabetes obesityrelated comorbidities fatty liver disease sleep apnoea measure new biomarkers established biobanks available serum plasma cohort least conventional vascular risk factor measured baseline plus BMI documented outcome covering least CHD event potentially also including incident cancers diabetes fatty liver disease Compare ability biomarkers predict obesityrelated outcome comparison conventionally measured risk factor simple demographic information Test predictive capacity promising biomarkers utilising sample taken trial held Industry participant EHRbiobank studies limited access sample biomarker analysis Confirming new metabolic biomarkers identified WP WP require EMIF bring additional biobanks cohort resource available biospecimens WP  Identify select individual pharmacological nonpharmacological intervention Ele Ferrannini UNIPI Stuart Kendrick GSK Janet Addison Amgen UNIPI COLEAD GSK COLEAD Amgen COLEAD UCPH Janssen PFIZER BI GOALS  OBJECTIVES main objective is pharmaceutical intervention work package designed deliver real world observational data data randomised controlled studies validating extreme phenotype approach classification obesity disease related obesity biomarkers identified work packages also designed test feasibility electronic healthcare record driven recruitment intervention trials subobjectives are Establish whether EHRs used conduct feasibility clinical trials Establish whether EHRs used contact patient recruitment clinical trial Better understanding relationship adverse effect  therapeutic effect extreme phenotype response prescribed drug Validate biomarkers predict therapeutic response interventional trial Utilize clinical trial data generated EFPIA partner investigate liver complication obesity content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation CONSORTIUM project consortium partnership teams academia small medium sized company member European Federation Pharmaceutical Industries Associations EFPIA EMIF team gather large number worldrenowned expert data access linkage Metabolic AD therapeutic area  country across Europe OrganisationPartner TypeCountry AcademiaDenmark AcademiaItaly Patient OrganisationLuxembourg EFPIAUK EFPIAGermany SMEUK SMEGermany SMEBelgium SMEUK AcademiaThe Netherlands AcademiaBelgium AcademiaGermany EFPIASwitzerland AcademiaItaly AcademiaItaly EFPIAUK AcademiaSweden AcademiaFinland AcademiaSpain AcademiaFrance AcademiaFinland EFPIABelgium AcademiaSweden AcademiaUK AcademiaGermany AcademiaThe Netherlands SMEFrance EFPIAGermany EFPIADenmark SMEItaly EFPIAUK SMEThe Netherlands AcademiaItaly EFPIAFrance SMESpain AcademiaEstonia AcademiaFinland EFPIABelgium AcademiaPortugal AcademiaSpain AcademiaBelgium AcademiaUK AcademiaDenmark AcademiaUK AcademiaUK AcademiaUK AcademiaUK AcademiaUK AcademiaFrance AcademiaItaly AcademiaGermany AcademiaGermany AcademiaGermany AcademiaGermany AcademiaBelgium AcademiaThe Netherlands content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation GOVERNANCE Project Management Boards daytoday management EMIF project done via various management boards specific responsibilities Project  Topic Leaders overall project coordination ensured by Bart Vannieuwenhuyse Janssen Pharmaceutica overall Project Coordinator Sir Simon Lovestone University Oxford overall Project CoCoordinator individual Topic managed tandem Topic Leaders Johan Van der Lei Erasmus Medical Center academic EMIFPlatform leader Nigel Hughes Janssen Pharmaceutica EFPIA EMIFPlatform leader Pieter Jelle Visser VU University Medical Center academic EMIFAD leader Johannes Streffer Janssen Pharmaceutica EFPIA EMIFAD leader Ulf Smith University Gothenburg academic EMIFMetabolic leader Dawn Waterworth GlaxoSmithKline EFPIA EMIFMetabolic Leader management board overall project level Operations TeamProgramme Board General Assembly responsible dealing daytoday operations crossTopical collaboration defining strategic focus EMIF individual Topic level Topicspecific governance defined ensure efficient management Topics Project management office Dedicated project management support project whole individual Topics provided partner Janssen Pharmaceutica Synapse Research Management Partners Concentris GmbH GlaxoSmithKline Project Advisory Boards EMIF project receives advice strategic focus outcome via three independent advisory boards Ethical Advisory Board EAB EAB providing advice thesetting EMIFs appropriate governance structure addressing ethical legal privacy aspect pertaining reuse human health data within EMIF project EMIF EAB currently ha  members Prof Luciano Floridi Professor Philosophy Ethics Information Oxford Internet Institute University Oxford Turing Faculty Fellow Alan Turing Institute London chair EMIF EAB Prof Effy Vayena Professor Health Policy University Zrich Prof Burkhard Schfer Professor Computational Legal Theory University Edinburgh Director SCRIPT Centre IP law Prof ChristophLtge holder Peter Lscher Chair Business Ethics Technical University Munich Prof Peggy Valcke Professor ICT medium law KU Leuven Prof Ugo Pagallo Professor Jurisprudence Faculty Law University Turin Check detailed description EABs responsibility member PDF version summary overview EABs responsibility short bios member Senior Industry Board SIB SIBserves ultimate escalation point upon request provide strategic direction EMIF board composed senior leader participating EFPIA companies Scientific Advisory Board SAB Three SABs set provide advice individual Topics regarding scientific result overall course SAB composed expert nominated public private partner involved specific Topics content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation PUBLICATIONS  LINKTOPICTITLEREFERENCEAUTHORSDATE ADAge dependency risk factor cognitive declineBMC Geriatrics  Legdeur N Heymans MW Comijs HC Huisman M Maier AB Visser PJ ADThe EMIFAD PreclinAD study Study Design Baseline Cohort OverviewAlzheimers Res Ther  Aug Konijnenberg E Carter SF Ten Kate M den Braber A Tomassen J Amadi C et al ADCapturing Alzheimers disease pathological cascadeLancet Neurol  MarTijms BM Visser PJ ADAmyloid Tau Cognition Cognitively Normal Older Individuals Examining Necessity Adjust Biomarker Status Normative DataFront Aging Neurosci  Jun Bos I Vos SJ Jansen WJ Vandenberghe R Gabel S Estanga et al ADInterlaboratory Proficiency Processing scheme CSF aliquoting Implementation assessment based biomarkers Alzheimers DiseaseAlzheimers Research  TherapyLewczuk P Gaignaux A Kofanova O Ermann N Betsou F Brandner et al ADThe EMIFAD Multimodal Biomarker Discovery study design method cohort characteristicsAlzheimers Res Ther  Jul Bos I Vos SJ Vandenberghe R Scheltens P Engelborghs S Frisoni G et al ADMRI predictor amyloid pathology result EMIFAD multimodal biomarker discovery studyAlzheimers Research  TherapyTen Kate M Redolfi A Peira E Bos I Vos SJ Vandenberghe R et al ADCSF nonphosphorylated Tau biomarker discrimination AD CJDAnn Clin Transl Neurol  Jul  Ermann N Lewczuk P Schimetz M Lange P Knipper T Goebel et al ADDiagnostic value cerebrospinal fluid tau neurofilament progranulin definite frontotemporal lobar degenerationAlzheimers Res Ther  Mar Goossens J Bjerke M Van Mossevelde S Van den Bossche T Goeman J De Vil B et al ADWhite paper Society CSF Analysis Clinical Neurochemistry Overcoming barrier biomarker development clinical translationAlzheimers Res Ther  Mar Teunissen CE Otto M Engelborghs S Herukka SK Lehmann S Lewczuk P et al ADNeurogranin Cerebrospinal Fluid Biomarker Alzheimer Disease Assay Comparison StudyClin Chem  JunWillemse EAJ De Vos A Herries EM Andreasson U Engelborghs S van der Flier WM ADAdded Diagnostic Value Cerebrospinal Fluid Biomarkers Differential Dementia Diagnosis AutopsyConfirmed CohortJ Alzheimers Dis Niemantsverdriet E Feyen BFE Le Bastard N Martin JJ Goeman J De Deyn PP Bjerke M Engelborghs S ADLong NonCoding RNAs Associated Metabolic Traits Human White Adipose TissueEBioMedicine  AprGao H Kerr A Jiao H Hon CC Rydn M Dahlman I Arner P ADGray matter network disruption amyloid beta cognitively normal adultsFront Aging Neurosci  Mar Ten Kate M Visser PJ Bakardjian H Barkhof F Sikkes SAM van der Flier WM et al ADPlasma neurofilament light potential biomarker neurodegeneration Alzheimers diseaseAlzheimers Res Ther  Jul Lewczuk P Ermann N Andreasson U Schultheis C Podhorna J Spitzer P et al ADAmyloid oligomers AOs Alzheimers diseaseJ Neural Transm Vienna  FebMroczko B Groblewska M LitmanZawadzka A Kornhuber J Lewczuk P ADA Specific Reduction A vs Universal Loss Peptides CSF Differentiates Alzheimers Disease Meningitis Multiple SclerosisFront Aging Neurosci  May Spitzer P Lang R Oberstein TJ Lewczuk P Ermann N Huttner HB Masouris I Kornhuber J Kdel U Maler JM ADWhite matter hyperintensities vascular risk factor monozygotic twinsNeurobiol Aging  JunTen Kate M Sudre CH den Braber A Konijnenberg E Nivard MG Cardoso MJ Scheltens P Ourselin S Boomsma DI Barkhof F Visser PJ ADAssociation Cerebral Amyloid Aggregation Cognitive Functioning Persons Without DementiaJAMA Psychiatry  Jan Jansen WJ Ossenkoppele R Tijms BM Fagan AM Hansson O Klunk et al ADScreening Potential Adipokines Identifies SA Marker Pernicious Adipose Tissue Insulin ResistanceInt J Obes Lond  Jan Arner P Petrus P Esteve D Boulomi A Nslund E Thorell et al ADCerebrospinal fluid blood biomarkers neurodegenerative dementias update Consensus Task Force Biological Markers Psychiatry World Federation Societies Biological PsychiatryWorld J Biol Psychiatry  JunLewczuk P Riederer P OBryant SE Verbeek MM Dubois B Visser PJ et al ADDementia prevalence incidence federation European Electronic Health Record databases European Medical Informatics Framework resourceAlzheimers Dement  FebPerera G Pedersen L Ansel D Alexander M Arrighi HM Avillach P et al ADCellular Receptors Amyloid Oligomers AOs Alzheimers DiseaseInt J Mol Sci  Jun Mroczko B Groblewska M LitmanZawadzka A Kornhuber J Lewczuk P ADAmyloid production aggregation preclinical Alzheimers disease  monozygotic twin studyAlzheimers Res Ther  Aug Konijnenberg E Carter SF Ten Kate M den Braber A Tomassen J Amadi C et al MetabolicGammaglutamyltranspeptidase fraction obese subject type  diabetes relation insulin sensitivity effect bariatric surgeryObes Surg  MayFranzini M Musetti V Guarino D Caponi L Paolicchi A Emdin M Ferrannini E Nannipieri M MetabolicElevated Plasma Levels Hydroxyisobutyric Acid Associated Incident Type  DiabetesEBioMedicine  JanMardinoglu A Gogg S Lotta LA Stankov A Nerstedt A Boren J et al MetabolicSystems biology hepatology approach applicationsNat Rev Gastroenterol Hepatol  JunMardinoglu A Boren J Smith U Uhlen M Nielsen J et al PlatformKey Ethical Challenges European Medical Information FrameworkMinds Machines doiorgsForidi L Luetge C Pagallo U Schefr B Valcke P Vayena E et al PlatformMONTRA agile architecture data publishing discoveryComput Methods Programs Biomed  JulSilva LB Trifan A Oliveria JL PlatformA methodology finegrained access control exposing biomedical dataStud Health Technol Inform Trifan A van der Lei J Daz C Oliveira JL PlatformReal world data reveal diagnostic gap nonalcoholic fatty liver diseaseBMC Med   Alexander M Loomis K FairburnBeech J Van der Lei J DuarteSalles T PrietoAlhambra et al PlatformA modular workflow management frameworkIn Proceedings th International Joint Conference Biomedical Engineering Systems Technologies  Volume  HEALTHINF  Almeida JR Ribeiro R Oliveira JL PlatformA methodology perform semiautomatic distributed EHR database queriesProceedings th International Joint Conference Biomedical Engineering Systems Technologies  Volume  HEALTHINF  Fajarda O Silva LB Rijnbeek PR Van Speybroeck M Oliveria JL PlatformA DeIdentification Pipeline Ultrasound Medical Images DICOM FormatJ Med Syst  May doi sMonteiro E Costa C Oliveria JL PlatformcomoRbidity R package systematic analysis disease comorbiditiesBioinformatics  Sep  GutirrezSacristn A Bravo A Giannoula A Myaer MA Sanz F Furlong LI PlatformIdentifying temporal pattern patient disease trajectory using dynamic time warping populationbased studySci Rep   Giannoula A Gutierrez Sacristn A Bravo A Sanz F Furlong LI  LINKTOPICTITLEREFERENCEAUTHORSDATE MetabolicHypoinsulinaemic hypoketotic hypoglycaemia due mosaic genetic activation PIkinaseEur J Endocrinol  Aug  Leiter SM Parker VER Welters A Knox R Rocha N Clark G et al MetabolicMuscle adipose tissue morphology insulin sensitivity betacell function diabetic nondiabetic obese patients effect bariatric surgerySci Rep  Aug Camastra S Vitali A Anselmino M Gastaldelli A Bellini R Berta R et al MetabolicPlasma mannose level associated incident type  diabetes cardiovascular diseaseCell Metab  Aug Mardinoglu A Stankov A Lotta LA Kuusisto J Boren J Blher et al MetabolicImproving economics NASHNAFLD treatment use system biologyDrug Discov Today  OctBosley J Boren C Lee S Grtli M Nielsen J Boren J et al MetabolicConstitutive activation AKT human lead hypoglycemia without fatty liver metabolic dyslipidemiaJ Clin Endocrinol Metab  Aug Minic M Rocha N Harris J Groeneveld MP Leiter S Wareham N et al MetabolicInsulin resistance normal thyroid hormone levels prospective study metabolomic analysisAm J Physiol Endocrinol Metab  May EEFerrannini E Iervasi G Cobb J Ndreu R Nannipieri M MetabolicLongitudinal analysis steroid metabolome obese PCOS girl weight lossEndocr Connect  MayReinehr T Kulle A Rothermel J KnopSchmenn C Lass N Bosse C Holterhus PM ADThe frequency influence dementia risk factor prodromal Alzheimers diseaseNeurobiol Aging  AugBos I Vos SJ Frlich L Kornhuber J Wiltfang J Maier W et al ADDoes genetic risk help predict amyloid burden nondemented population Bayesian approachbioRxiv doiorgVoyle N Jansen W Keohane A Patel H Folarin A Newhouse et al ADStrategic roadmap early diagnosis Alzheimers disease based biomarkersLancet Neurol  AugFrisoni GB Boccardi M Barkhof F Blennow K Cappa S Chiotis K et al ADAmyloidindependent atrophy pattern predict time progression dementia MCIAlzheimers Res Ther  Sep Ten Kate M Barkhof F Visser PJ Teunissen CE Scheltens P van der Flier WM Tijms BM ADCerebrovascular amyloid pathology predementia stages relationship neurodegeneration cognitive declineAlzheimers Res Ther  Dec Bos I Verhey FR Ramakers IHGB Jacobs HIL Soininen H FreundLevi et al ADClinical validity medial temporal atrophy biomarker Alzheimers disease context structured phase development frameworkNeurobiol Aging  ApreTen Kate M Barkhof F Boccardi M Visser PJ Jack CR Jr Lovblad KO et al ADCognitive functioning individual aged  year older withoutdementia systematic reviewAgeing Res Rev  JulLegdeur N Binnekade TT Otten RH Badissi M Scheltens P Visser PJ Maier AB ADBrain Amyloid Pathology Cognitive Function  Alzheimer Disease Without DementiaJAMA Visser PJ Tijms B ADAssociation blood lipid Alzheimers Disease comprehensive lipidomics analysisAlzheimers Dement  FebProitsi P Kim M Whiley L Simmons A Sattlecker M Velayudhan L et al PlatformReal world big data clinical research drug developmentDrug Discov Today  MarSingh G Schulthess D Hughes N Vannieuwenhuyse B Kalra D PlatformLa Reutilizacin de la Informacin de la Historia Clnica Electrnica para la Investigacin De la Medicina Traslacional la Medicina de Precisin el nuevo paradigma Learning Health SystemIS Revista de la Sociedad Espaola de Informtica SaludMayer MA PlatformGeneral guideline biomedical software developmentFResearch  Silva LB Jimenez RC Blomberg N Luis Oliveira J PlatformData Integration Sharing Supporting Drug RDComprehensive Medicinal Chemistry III vol  pp Sanz F PlatformThe launch European Institute innovation health dataJournal Medicines Development Sciences  Kalra D Sundgren M Claerhout B et al PlatformUsing Electronic Health Records Assess Depression Cancer ComorbiditiesStud Health Technol Inform Mayer MA GutierrezSacristan A Leis A De La Pea S Sanz F Furlong LI PlatformNine Princples Semantic HarmonizationAMIA Annu Symp Proc   Cunningham JA Van Speybroeck M Kalra D Verbeeck R MetabolicCephalic phase insulin secretion response meal unrelated family history Type  diabetesPLoS One  Mar eEliasson B Rawshani A Axelsen M Hammarstedt A Smith U MetabolicObesityinsulin resistance rather liver fat increase coagulation factor activity expression humansThromb Haemost  Jan Lallukka S Luukkonen PK Zhou Y Isokuortti E Leivonen M Juuti et al ADMitochondrial gene altered blood early Alzheimers diseaseNeurobiol Aging  MayLunnon K Keohane A Pidsley R Newhouse S RiddochContreras J Thubron EB et al ADThe frequency influence dementia risk factor prodromal Alzheimers diseaseNeurobiol Aging  AugBos I Vos SJ Frlich L Kornhuber J Wiltfang J Maier W et al MetabolicGenomewide DNA promoter methylation transcriptome analysis human adipose tissue unravels novel candidate gene obesityMol Metab  Jan  Keller M Hopp L Liu X Wohland T Rohde K Cancello R et al ADFunctional effective whole brain connectivity using magnetoencephalography identify monozygotic twin pairsSci Rep  Aug Demuru M Gouw AA Hillebrand A Stam CJ van Dijk BW Scheltens P et al  LINKTOPICTITLEREFERENCEAUTHORSDATE MetabolicIntegrated Network Analysis Reveals Association Plasma Mannose Levels Insulin ResistanceCell Metab  Jul Lee S Zhang C Kilicarslan M Piening BD Bjornson E Hallstrm BM et al ADCerebrospinal Fluid A Corresponds Better A Amyloid PET Alzheimers DiseaseJ Alzheimers Dis Lewczuk P Matzen A Blennow K Parnetti L Molinuevo JL Eusebi P Kornhuber J Morris JC Fagan AM ADComplement Biomarkers predictor disease progression Alzheimers diseaseJ Alzheimers Dis  Sep Hakobyan S Harding K Aiyaz M Hye A Dobson R Baird A Liu B Harris CL Lovestone S Morgan BP PlatformIdentificare casi di diabete tipo  una rete di fonti di dati eterogenee la strategia del progetto EMIFNot Ist Super Sanit Roberto G Gini R MetabolicA systematic review aetiological predictive biomarkers risk developing type  diabetesPLoS One  Oct eAbbasi A Sahlqvist AS Lotta L Brosnan JM Vollenweider P Giabbanelli P et al MetabolicInsulin resistance uncoupled dyslipidemia due Cterminal PIKR mutationsJCI Insight  Oct eHuangDoran I Tomlinson P Payne F Gast A Sleigh A Bottomley W et al ADNonPhosphorylated Tau Potential Biomarker Alzheimers Disease Analytical Diagnostic CharacterizationJ Alzheimers Dis Lewczuk P Lelental N Lachmann I Holzer M Flach K Brandner et al PlatformBig Data Technologies Healthcare Needs opportunity challengesBDVA Valencia Summit White paperTF Healthcare Subgroup Big Data Value Association MetabolicGenetic Predisposition Impaired Metabolism BranchedChain Amino Acids Risk Type  Diabetes Mendelian Randomization AnalysisPLoS Med  Nov eLotta LA Scott RA Sharp SJ Burgess S Luan J Tillin et al ADGenetic risk plasma tau marker amyloidbeta tau burden cerebrospinal fluidJ Alzheimers Dis   Voyle N Patel H Folarin A Newhouse S Johnston C Visser PJ et al MetabolicNonalcoholic fatty liver disease risk type  diabetesBest Pract Res Clin Endocrinol Metab  JunLallukka S YkiJrvinen H PlatformIdentifying Cases Type  Diabetes Heterogeneous Data Sources Strategy EMIF ProjectPLoS ONE  eRoberto G Leal I Sattar N Loomis AK Avillach P Egger P et al MetabolicHepatic ceramides dissociate steatosis insulin resistance patient nonalcoholic fatty liver diseaseJ Hepatol  MayLuukkonen PK Zhou Y Sdevirta S Leivonen M Arola J Orei M Hytylinen T YkiJrvinen H MetabolicPhosphorylated IGFBP noninvasive predictor liver fat NAFLDSci Rep  Apr Petj EM Zhou Y Havana M Hakkarainen A Lundbom N Ihalainen J YkiJrvinen H PlatformData Safe Havens Trust Toward Common Understanding Trusted Research Platforms Governing Secure Ethical Health ResearchJMIR Med Inform  Jun eLea NC Nicholls J Dobbs C Sethi N Cunningham J Ainsworth J Heaven M Peacock T Peacock A Jones K Laurie G Kalra D ADGenetic variation underlying Alzheimers disease evidence genomewide association study beyondLancet Neurol  JulCuyvers E Sleegers K ADA Decade Cerebrospinal Fluid Biomarkers Alzheimers Disease BelgiumJ Alzheimers Dis  Aug Somers C Struyfs H Goossens J Niemantsverdriet E Luyckx J De Roeck N De Roeck E De Vil B Cras P Martin JJ De Deyn PP Bjerke M Engelborghs S ADValidation microRNAs Cerebrospinal Fluid Biomarkers Different Forms Dementia Multicenter StudyJ Alzheimers Dis  Apr Mller M Kuiperij HB Versleijen AA Chiasserini D Farotti L Baschieri F Parnetti L Struyfs H De Roeck N Luyckx J Engelborghs S Claassen JA Verbeek MM ADsTREM cerebrospinal fluid level potential biomarker microglia activity earlystage Alzheimers disease associate neuronal injury markersEMBO Mol Med  May SurezCalvet M Kleinberger G Araque Caballero M Brendel M Rominger A Alcolea D Fortea J Lle A Blesa R Gispert JD SnchezValle R Antonell A Rami L Molinuevo JL Brosseron F Traschtz A Heneka MT Struyfs H Engelborghs S Sleegers K Van Broeckhoven C Zetterberg H Nellgrd B Blennow K Crispin A Ewers M Haass C MetabolicRisk factor spontaneously selfreported postprandial hypoglycemia bariatric surgeryJ Clin Endocrinol Metab  OctNannipieri M Belligoli A Guarino D Busetto L Moriconi D Fabris R Mari A Baldi S Anselmino M Foletto M Vettor R Ferrannini E MetabolicAdipose circulating CCL level associate metabolic risk factor womenJ Clin Endocrinol Metab  Jul jcEriksson Hogling D Petrus P Gao H Bckdahl J Dahlman I Laurencikiene J Acosta J Ehrlund A Nslund E Kulyte A Mejhert N Andersson DP Arner P Rydn M MetabolicThe epigenetic signature systemic insulin resistance obese womenDiabetologia  NovArner P Sahlqvist AS Sinha I Xu H Yao X Waterworth D Rajpal D Loomis AK Freudenberg JM Johnson T Thorell A Nslund E Ryden M Dahlman I ADGray matter network disruption amyloid beta cognitively normal adultsNeurobiol Aging  JanTijms BM Kate MT Wink AM Visser PJ Ecay M Clerigue M Estanga A Garcia Sebastian M Izagirre A Villanua J Martinez Lage P van der Flier WM Scheltens P Sanz Arigita E Barkhof F ADDiagnostic Impact Cerebrospinal Fluid Biomarker PreAnalytical Variability Alzheimers DiseaseJ Alzheimers Dis Niemantsverdriet E Goossens J Struyfs H Martin JJ Goeman J De Deyn PP Vanderstichele H Engelborghs S ADImpact APOEe family history dementia gray matter atrophy cognitively healthy middleaged adultsNeurobiol Aging  FebTen Kate M SanzArigita EJ Tijms BM Wink AM Clerique M GarciaSebastian M Izagirre A EcayTorres M Estanga A Villanua J Vrenken H Visser PJ MartinezLage P Barkhof F PlatformSemantic Knowledge Base Construction Radiology ReportsHealthinf Biostec  ISBN  page Monteiro E Sernadela P Matos S Costa C Oliveira JL ADComparison Different Matrices Potential Quality Control Samples Neurochemical Dementia DiagnosticsJ Alzheimers Dis  Mar Lelental N Brandner S Kofanova O Blennow K Zetterberg H Andreasson U et al  LINKTOPICTITLEREFERENCEAUTHORSDATE PlatformPsyGeNET knowledge platform psychiatric disorder genesBioinformatics  Sep GutirrezSacristn A Grosdidier S Valverde O Torrens M Bravo  Piero J Sanz F Furlong LI ADAlzheimers disease  Recent biomarker development relation updated diagnostic criteriaClin Chim Acta  Sep Hglund K Fourier A PerretLiaudet A Zetterberg H Blennow K Portelius E ADValidation Erlangen Score Algorithm prediction development dementia due AD predementia subjectsJ Alzheimers Dis Sep Lewczuk PKornhuber JToledo JBTrojanowski JQKnapikCzajka MPeters OWiltfang JShaw LM ADAgestratified prevalence mild cognitive impairment dementia European populations systematic reviewJ Alzheimers Dis Sep Alexander MPerera GFord LArrighi HMFoskett NDebove CNovak GGordon MF ADA novel multitissue diagnostic healthy ageing determine cognitive health status using blood RNAGenome Biol   Sood SGallagher IJ Lunnon KRullman EKeohane ACrossland HPhillips BE Cederholm TJensen Tvan Loon LJCLannfelt LKraus WEAtherton PJHoward R Gustafsson THodges ATimmons JA ADBoosting translational research Alzheimers disease Europe Innovative Medicine Initiative AD research platformAlzheimers Dement SepVaudano EVannieuwenhuyse BVan Der Geyten Svan der Lei JVisser PJStreffer JRitchie CMcHale DLovestone SHofmannApitius MTruyen LGoldman M ADNo evidence suggest use acetylcholinesterase inhibitor confounds result two bloodbased biomarker study Alzheimers diseaseJ Alzheimers Dis Aug Chiam JTLunnon KVoyle NProitsi PCoppola GGeschwind DNelson SJohnston CSoininen HKloszewska IMecocci PTsolaki MVellas BHodges ALovestone SNewhouse SDobson RJKiddle SJSattlecker M ADBiomarkers Alzheimers disease controversial topicLancet Neurol AugFrisoni GBVisser PJ ADGeneralizability disease state index prediction model identifying patient progressing mild cognitive impairment Alzheimers diseaseJ Alzheimers DisHall AMuozRuiz MMattila JKoikkalainen JTsolaki MMecocci PKloszewska IVellas BLovestone SVisser PJLtjonen JSoininen HAlzheimer DiseaseNeuroimaging InitiativeAddNeuroMed consortiumDESCRIPA Kuopio LMCI ADBlood protein marker Neocortical Amyloid Burden candidate study using SOMAscan technologyJ Alzheimers Dis Jun Voyle NBaker DBurnham SCCovin AZhang ZSangurdekar DPTan Hehir CABazenet CLovestone SKiddle SDobson RJ ADCerebrospinal fluid PtauP biomarker improved differential diagnosisFront Neurol Jun Struyfs HNiemantsverdriet EGoossens JFransen EMartin JJDe Deyn PPEngelborghs S ADPlasma protein biomarkers Alzheimers disease endophenotypes asymptomatic older twins early cognitive decline regional brain volumesTransl Psychiatry Jun eKiddle SJSteves CJMehta MSimmons AXu XNewhouse SSattlecker MAshton NJBazenet CKillick RAdnan JWestman ENelson SSoininen HKloszewska IMecocci PTsolaki MVellas BCurtis CBreen GWilliams SCLovestone SSpector TDDobson RJ MetabolicAssociations potentially modifiable risk factor Alzheimers disease Mendelian randomization studyPLoS Med Jun estergaard SDMukherjee SSharp SJProitsi PLotta LADay FPerry JRBoehme KLWalter SKauwe JSGibbons LEAlzheimers Disease Genetics ConsortiumGERAD ConsortiumEPICInterAct ConsortiumLarson EBPowell JFLangenberg CCrane PKWareham NJScott RA ADPrevalence cerebral amyloid pathology person without dementia metaanalysisJAMA  May   Jansen WJOssenkoppele RKnol DLTijms BM Scheltens PVerhey FRJ Visser PJ Amyloid Biomarker Study Group ADTemporal evolution biomarkers cognitive marker asymptomatic MCI dementia stage Alzheimers diseaseAlzheimers Dement MayBertens DKnol DLScheltens PVisser PJAlzheimers Disease Neuroimaging Initiative ADImportance impact preanalytical variable Alzheimers disease biomarker level cerebrospinal fluidClin Chem Apr  Le Bastard N De Deyn PP Engelborghs S ADPrevalence prognosis Alzheimers disease mild cognitive impairment stageBrain MayPt Vos SJVerhey FFrlich LKornhuber JWiltfang JMaier WPeters ORther ENobili FMorbelli SFrisoni GBDrzezga ADidic Mvan Berckel BNSimmons ASoininen HKloszewska IMecocci PTsolaki MVellas BLovestone SMuscio CHerukka SKSalmon EBastin CWallin ANordlund Ade Mendona ASilva DSantana ILemos REngelborghs SVan der Mussele SAlzheimers Disease Neuroimaging InitiativeFreundLevi YWallin KHampel Hvan der Flier WScheltens PVisser PJ MetabolicAdipose Tissue Morphology Predicts Improved Insulin Sensitivity Following Moderate Weight LossInt J Obes Lond JunErikssonHogling DAndersson DPBckdahl JHoffstedt JRssner SThorell AArner EArner PRydn M ADLinking genetics brain change Alzheimers disease sparse whole genome association scan regional MRI volume ADNI AddNeuroMed cohortsJ Alzheimers DisKhondoker MNewhouse SWestman EMuehlboeck JSMecocci PVellas BTsolaki MKloszewska ISoininen HLovestone SDobson RSimmons AAddNeuroMed consortiumAlzheimers Disease Neuroimaging Initiative ADAn Integrated Workflow Multiplex CSF Proteomics PeptidomicsIdentification Candidate Cerebrospinal Fluid Biomarkers Alzheimers DiseaseJ Proteome Res Feb Hltt MMinthon LHansson OHolmnLarsson JPike IWard MKuhn KRetschi UZetterberg HBlennow KGobom J ADTDP possible biomarker frontotemporal lobar degeneration systematic review existing antibodiesActa Neuropathol Commun Apr Goossens JVanmechelen ETrojanowski JQLee VMVan Broeckhoven Cvan der Zee JEngelborghs S ADOverdiagnosing vascular dementia using structural brain imaging dementia workupJ Alzheimers DisNiemantsverdriet EFeyen BFLe Bastard NMartin JJGoeman JDe Deyn PPEngelborghs S ADPlasma lipidomics analysis find long chain cholesteryl ester associated Alzheimers diseaseTransl Psychiatry Jan eProitsi PKim MWhiley LPritchard MLeung RSoininen HKloszewska IMecocci PTsolaki MVellas BSham PLovestone SPowell JFDobson RJLegidoQuigley C ADDiagnostic accuracy CSF amyloid isoforms early differential dementia diagnosisJ Alzheimers DisStruyfs HVan Broeck BTimmers MFransen ESleegers KVan Broeckhoven CDe Deyn PPStreffer JRMercken MEngelborghs S PlatformReuse EHRs Support Clinical Research Hospital ReferenceStud Health Technol InformMayer MAFurlong LITorre PPlanas ICots FIzquierdo EPortabella JRovira JGutierrezSacristan ASanz F ADBlood protein predictor brain amyloid enrichment clinical trialsAlzheimers  Dementia Diagnosis Assessment  Disease Monitoring   Ashton NJ Kiddle SJ Graf J Ward M Baird AL Hye A Westwood S Wonga KV Dobson RJ Rabinovici GD Miller BL Rosen HJ Torres A Zhang Z Thurfjell L Covini A Tan Hehir C Baker D Bazenet C Lovestone S behalf AIBL Research Group MetabolicCirculating triacylglycerol signature insulin sensitivity NAFLD associated EK variant TMSFJ Hepatol  Mar Zhou Y Llaurad G Oresic M Hytylinen T OrhoMelander M YkiJrvinen H ADLongitudinal protein change blood plasma associated rate cognitive decline Alzheimers diseaseJ Alzheimers DisSattlecker M Khondoker M Proitsi P Williams S Soininen H Kloszewska I Mecocci P Tsolaki M Vellas B Lovestone S Dobson RJ MetabolicAdipose tissue fatty acid chain length monounsaturation increase obesity insulin resistanceSci Rep  Dec Yew Tan C Virtue S Murfitt S Robert LD Phua YH Dale M Griffin JL Tinahones F Scherer PE VidalPuig A MetabolicBody mass index risk nonalcoholic fatty liver disease Two electronic health record prospective studiesJ Clin Endocrinol Metab  MarLoomis AK Kabadi S Preiss D Hyde C Bonato V St Louis M Desai J Gill JM Welsh P Waterworth D Sattar N MetabolicDefinitions Metabolic Health Risk Future Type  Diabetes BMI categories Systematic Review Network MetaAnalysisDiabetes Care  NovLotta LA Abbasi A Sharp SJ Sahlqvsit AS Waterworth D Brosnan JM Scott RA Langenberg C Wareham NJ MetabolicEvidence causal association hyperinsulinaemia endometrial cancer Mendelian randomization analysisJ Natl Cancer Inst  Jul  pii djvNead KT Sharp SJ Thompson DJ Painter JN Savage DB Semple RK Barker A Australian National Endometrial Cancer Study Group ANECS Perry JR Attia J Dunning AM Easton DF Holliday E Lott LA OMara T McEvoy M Pharoah PD Scott RJ Spurdle AB Langenberg C Wareham NJ Scott RA ADAlzheimers disease report th Kuopio Azheimer symposiumNeurodegener Dis Manag  OctHaapasalo A Pikkarainen M Soininen H ADA Pathway Based Classification Method Analyzing Gene Expression Alzheimers Disease DiagnosisJ Alzheimers Dis  Oct Voyle N Keohane A Newhouse S Lunnon K Johnston C Soininen H Kloszewska I Mecocci P Tsolaki M Vellas B Lovestone S Hodges A Kiddle S Dobson RJ MetabolicType  diabetes migrant South Asians mechanisms mitigation managementLancet Diabetes Endocrinol  DecSattar N Gill JM MetabolicExtensive weight loss reveals distinct gene expression change human subcutaneous visceral adipose tissueSci Rep  Oct Mardinoglu A Heiker JT Grtner D Bjrnson E Schn MR Flehmig G Klting N Krohn K Fasshauer M Stumvoll M Nielsen J Blher M PlatformChallenges opportunity exploring patientlevel dataBiomed Res Int Lopes P Bastio Silva L Oliveira JL MetabolicThe UKK project identifies rare variant health diseaseNature  Oct UKK Consortium Walter K Min JL Huang J Crooks L Memari Y McCarthy S Perry JR Xu C Futema M Lawson D Iotchkova V Schiffels S Hendricks AE Danecek P Li R Floyd J Wain LV Barroso I Humphries SE Hurles ME Zeggini E Barrett JC Plagnol V Richards JB Greenwood CM Timpson NJ Durbin R Soranzo N ADThe genetic landscape Alzheimers disease clinical implication perspectivesGenet Med  Aug Van Cauwenberghe C Van Broeckhoven C Sleegers K MetabolicThe epigenetic signature subcutaneous fat linked altered expression gene implicated lipid metabolism obese womenClin Epigenetics  Sep Arner P Sinha I Thorell A Rydn M DahlmanWright K Dahlman I MetabolicTyrosine associated insulin resistance longitudinal metabolomic profiling obese childrenJ Diabetes Res Hellmuth C Kirchberg FF Lass N Harder U Peissner W Koletzko B Reinehr T ADCurrent development dementia risk prediction modelling updated systematic reviewPLoS One  Sep Tang EY Harrison SL Errington L Gordon MF Visser PJ Novak G Dufouil C Brayne C Robinson L Launer LJ Stephan BC PlatformCaf Variome GeneralPurpose Software Making GenotypePhenotype Data Discoverable Restricted Open Access ContextsHum Mutat  OctLancaster O Beck T Atlan D Swertz M Thangavelu D Veal C Dalgleish R Brookes AJ PlatformArchitecture summarize patientlevel data across border countriesStud Health Technol Inform Bastio Silva LA Das C van der Lei J Oliveira JL ADBlood metabolite marker neocortical amyloid burden Discovery enrichment using candidate proteinsTransl Psychiatry  Jan eVoyle N Kim M Proitsi P Ashton NJ Baird AL Bazenet C Hye A Westwood S Chung R Ward M Rabinovici GD Lovestone S Breen G LegidoQuigley C Dobson RJ Kiddle SJ ADCterminal neurogranin increased cerebrospinal fluid unchanged plasma Alzheimers diseaseAlzheimers Dement  DecDe Vos A Jacobs D Struyfs H Fransen E Andersson K Portelius E Andreasson U De Surgeloose D Hernalsteen D Sleegers K Robberecht C Van Broeckhoven C Zetterberg H Blennow K Engelborghs S Vanmechelen E ADPrevalence Amyloid PET Positivity Dementia Syndromes MetaAnalysisJAMA  May Ossenkoppele R Jansen WJ Rabinovici GD Knol DL van der Flier WM van Berckel BN Scheltens P Visser PJ Amyloid PET Study Group Verfaillie SC Zwan MD Adriaanse SM Lammertsma AA Barkhof F Jaqust WJ Miller BL Rosen HJ Landau SM Villemagne VL Rowe CC Lee DY Na DL Seo SW Sarazin Roe CM Sabri O Barthel H Koglin N Hodges J Leyton CE Vandenberghe R van Laere K Drzezga A Forster S Grimmer T SnchezJuan P Carril JM Mok V Camus V Klunk WE Cohen AD Meyer PT Hellwig S Newberg A Frederiksen KS Fleisher AS Mintun MA Wolk DA Nordberg A Rinne JO Chtelat G Lleo A Blesa R Fortea J Madasen K Rodrigue KM Brooks DJ MetabolicThe fat cell epigenetic signature postobese woman characterized global hypomethylation differential DNA methylation adipogenesis genesInt J Obes Lond  JunDahlman I Sinha I Gao H Brodin D Thorell A Rydn M Andersson DO Henriksson J Perfilyev A Ling C DahlmanWright K Arner P ADAlzheimers disease cerebrospinal fluid biomarker cognitively normal subjectsBrain  SepPtToledo JB Zetterberg H van Harten AC Glodzik L MartinezLage P BocchioChiavetto L Rami L Hansson O Sperling R Engelborghs S Osorio RS Vanderstichele H Vandijck M Hampel H Teipl S Moghekar A Albert M Hu WT Monge Argils JA Gorostidi A Teunissen CE De Deyn PP Hyman BT Molinuevo JL Frisoni GB Linazasoro G de Leon MJ van der Flier WM Scheltens O Blennow K Shaw LM Trojanowski JQ Alzheimers Disease Neuroimaging Initiative ADDiffusion kurtosis imaging biomarker early diagnosis Alzheimers diseaseJ Alzheimers Dis Struyfs H Van Hecke W Veraart J Sijbers J Slaets S De Belder M Wuyts L Peters B Sleegers K Robberecht C Van Broeckhoven C De Belder F Parizel PM Engelborghs S  LINKTOPICTITLEREFERENCEAUTHORSDATE ADA SNP Alzheimer risk score correlate family history onset age CSF AAlzheimers Dement Jun  pii SSleegersBettensDe RoeckVan CauwenbergheCuyversVerheijen JStruyfs HVan Dongen JVermeulen SEngelborghs SVandenbulcke MVandenberghe RDe Deyn PPVan Broeckhoven CBELNEU consortium ADDiagnostic value MIBG cardiac scintigraphy differential dementia diagnosisInt J Geriatr Psychiatry  AugSlaets S Van Acker F Versijpt J Hauth L Goeman J Martin JJ De Deyn PP Engelborghs S MetabolicFamily history type  diabetes increase risk obesity complications type  diabetes disease inappropriate lipid storageJ Intern Med MayCederberg HStanckov AKuusisto JLaakso MSmith U MetabolicType  diabetes disease ectopic fatBMC Med  Aug Sattar N Gill JM ADTemporal evolution biomarkers cognitive marker asymptomatic MCI dementia stage Alzheimers diseaseAlzheimers Dement  MayBertens D Knol DL Scheltens P Visser PJ Alzheimers Disease Neuroimaging Initiative ADCirculating Proteomic Signatures Chronological AgeJ Gerontol Biol Sci Med Sci JulMenni CKiddle SJMangino MViuela APsatha MSteves CSattlecker MBuil ANewhouse SNelson SWilliams SVoyle NSoininen HKloszewska IMecocci PTsolaki MVellas BLovestone SSpector TDDobson RValdes AM MetabolicHypomorphism human NSMCE linked primordial dwarfism insulin resistanceJ Clin Invest SepPayne FColnaghi RRocha NSeth AHarris JCarpenter GBottomley WEWheeler EWong SSaudek VSavage DORahilly SCarel JCBarroso IODriscoll MSemple R ADDepression mild cognitive impairment associated progression Alzheimers disease longitudinal studyJ Alzheimers Dis Van der Mussele S Fransen E Struyfs H Luyckx J Marin P Saerens J Somers N Goeman J De Deyn PP Engelborghs S ADPlasma protein predict conversion dementia prodromal diseaseAlzheimers Dement NovHye ARiddochContreras JBaird ALAshton NJBazenet CLeung RWestman ESimmons ADobson RSattlecker MLupton MLunnon KKeohane AWard MPike IZucht HDPepin DZheng WTunnicliffe ARichardson JGauthier SSoininen HKloszewska IMecocci PTsolaki MVellas BLovestone S MetabolicMutations disrupting Kennedy phosphatidylcholine pathway human congenital lipodystrophy fatty liver diseaseProc Natl Acad Sci U A Jun Payne FLim KGirousse ABrown RJKory NRobbins AXue YSleigh ACochran EAdams CDev Borman ARusselJones DGorden PSemple RKSaudek VORahilly SWalther TCBarroso ISavage DB PlatformEgas collaborative interactive document curation platformDatabase Oxford Jun  pii bauCampos DLoureno JMatos SOliveira JL ADValidation ADCSFindex autopsyconfirmed Alzheimers disease patient healthy controlsJ Alzheimers DisStruyfs H Molinuevo JL Martin JJ De Deyn PP Engelborghs S MetabolicChanges serum metabolite profile obese child weight lossEur J Nutr MarReinehr T Wolters B Knop C Lass N Hellmuth C Harder U Peissner W Wahl S Grallert H Adamski J Illig T Prehn C Yu Z WangSattler R Koletzko B AD MetabolicAdvanced glycation end products dementia diabetesProc Natl Acad Sci U A Apr Lovestone S Smith U MetabolicA populationbased study prevalence NASH using score validated liver histologyJ Hepatol  AprHyysalo J Mnnist VT Zhou Y Arola J Krj V Leivonen M Juuti A Jaser N Lallukka S Kkel P Venesmaa S Simonen M Saltevo J Moilanen L KorpiHyvalti E KeinnenKiukaanniemi S Oksa H OrhoMelander M Valenti L Fargion S Pihlajamki J Peltonen M YkiJrvinen H MetabolicCirculating Triacylglycerol Signatures Nonalcoholic Fatty Liver Disease Associated IM Variant PNPLA ObesityDiabetes  JanHyysalo J Gopalacharyulu Bian H Hytylinen T Leivonen M Jaser N Juuti A Honka MJ Nuutila P Olkkonen VM Oresic M YkiJrvinen H MetabolicAdipose Tissue CIDEA Associated Independently Weight Variation Change Insulin Resistance Longitudinal Weight Control Dietary Program Obese IndividualsPLoS One  Jul eMonastier E Djean S Le Gall C Saris WH Langin D Viguerie N PlatformMedical imaging archiving comparison several NoSQL solutionsBHI  JunLAB Silva L Beroud C Costa JL Oliveira PlatformNormalizing medical imaging archive dose quality assurance productivity auditingMeMeA  JunLAB Silva L Ribeiro C Costa JL Oliveira Santos PlatformSemantic search DICOM repositories IEEE International Conference Healthcare Informatics ICHI  Sept  pLAB Silva C Costa JL Oliveira  LINKTOPICTITLEREFERENCEAUTHORSDATE ADUnresolved question Alzheimers research  biomarkers helpBiomark Med Zetterberg H MetabolicPrediction nonalcoholic fattyliver disease liver fat content serum molecular lipidsDiabetologia  OctOreic M Hytylinen T Kotronen A Gopalacharyulu P Nygren H Arola J Castillo S Mattila I Hakkarainen A Borra RJ Honka MJ Verrijken A Francque S Iozzo P Leivonen M Jaser N Juuti A Srensen TI Nuutila P Van Gaal L YkiJrvinen H ADPreclinical Alzheimers disease outcome longitudinal cohort studyLancet Neurol  OctVos SJ Xiong C Visser PJ Jasielec MS Hassenstab J Grant EA Cairns NJ Morris JC Holtzman DM Fagan AM content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation DELIVERABLES Deliverables EXECUTIVE SUMMARYTOPICDELIVERABLEDATE PlatformD  Final report outreach activities PlatformD  Final Business Plan PlatformD  EMIF Platform PlatformD  System implementation feedback evaluation report  PlatformD  Final suite module tool data analysis PlatformD  Final report data flow data integration processing linkage PlatformD  Final version data extraction software PlatformD  Final Report Harmonisation Semantics PlatformD  Final version EMIF Code Practice PlatformD  Final evaluation result roadmap future development MetabolicD  Scientific publication describing use clinical trial populationbased study investigate natural history NAFLD MetabolicD  Legal Ethical Framework established MetabolicD  Evaluation liver function test placebo group existing clinical trial try determine factor influence nature MetabolicD  Study report manuscript calibration Framingham Risk score European NAFLD patients MetabolicD  Test efficiency respect identification clinical trial subject feasibility recruitment MetabolicD  Report describing test algorithm clinical outcome diverse population obese adult children MetabolicD  Development algorithm predict clinical outcome obese adult children MetabolicD  Protocols EMR data extraction analysis understand risk factor associated metabolic diseases MetabolicD  report prevalence overlap obesity four endpoint interest real world setting MetabolicD  Report describing association potentially causal biomarkers clinical outcome largescale casecohort studies MetabolicD  Report describing causal significance biomarkers associated metabolic consequence obesity MetabolicD  Completion report describing association  novel biomarkers emerging WP metabolic consequence obesity MetabolicD  Identify potential target drug development diagnostic test meet standard clinical sensitivity specificity criteria MetabolicD  Functional assessment novel biomarkers cell models MetabolicD  Identify novel biomarkers risk extreme phenotype exhibit adequate sensitivity specificity ADD  Screening algorithm tested defined ADD  Report crossvalidated plasma genetic CSF MRI marker diagnosis predementia AD ADD  Report joint study ADMetabolic ADD   Assays biomarkers clinical use ADD  Integrative model biomarkers different modalities ADD   novel combinatorial MRI marker algorithm prognosis ADD   Epigenomic profile associated abnormal AD CSF biomarkers ADD   GWASidentified SNPs abnormal CSF abeta tau hippocampal atrophy ADD   Metabolomics based plasma marker diagnosis ADD   Proteomic based plasma marker prognosis ADD   Proteomic based plasma marker diagnosis ADD  Definition extreme phenotype based resilience dementia ADD  Validated criterion presymptomatic AD prodromal AD ADD  Cohort cognitively normal subject year followup data ADD  Cohort cognitively normal subject AD biomarkers baseline data ADD  Dataset EHR data linked research cohort data ADD Novel combinatorial MRI marker algorithm diagnosis PlatformD Second framework evaluation result requirement v PlatformD First draft EMIF Ethical Code Practice PlatformD Second version harmonised information model associated terminology mapping PlatformD  System implementation feedback evaluation report iteration  PlatformD EMIF Platform version  PlatformD Update Business Plan  February  PMOD Technical Financial Annual Reports  ADD  Proteomic based CSF marker prognosis ADD  Private Remote Research database environment pooled data research cohorts ADD  Summary statistic cohort included ADD  Validated criterion presymptomatic AD prodromal AD ADD  Definition extreme phenotype based cognitive decline ADD  Prediction model cognitive decline ADD  Definition extreme phenotype based AD biomarkers ADD  Report overview available data sources MetabolicD  Establishing functional datawarehousing management MetabolicD  Analytical framework investigate metabolic predictor complication obesity MetabolicD  report describing systematic review candidate biomarkers prediction metabolic consequence obesity MetabolicD  Investigation causal nature association obesity selected obesityrelated complications MetabolicD  report describing association  candidate biomarkers metabolic trait   participant wellphenotyped metabolically phenotyped studies MetabolicD  report describing association metabolomic profile metabolic complication obesity   participant wellphenotyped metabolically phenotyped studies PlatformD  Platform requirement v evaluation plan PlatformD  Full database fingerprinting PlatformD  First version common data model associated terminology mapping PlatformD  Data extraction software v PlatformD  data management solution vertical projects version  PlatformD  EMIFPlatform version  PlatformD  Report business model data exploitation biosciences PlatformD  System implementation feedback evaluation report iteration  PlatformD  Extended specification semantic framework reference PlatformD  Evaluation technology tool available data analysis visualization PlatformD  Initial requirement set PlatformD  Market analysis usage model data source characterization PlatformD  Interim framework evaluation result requirement v PlatformD  Data extraction software v PlatformD  Interim report primary data flows benchmarking quality analyses PlatformD  Data analysis tool vertical project v PlatformD  data management solution vertical projects v PlatformD  EMIFPlatform version  PlatformD  Initial business model description PlatformD  Second version common data model associated terminology mapping PlatformD  First report outreach activities leveraging related initiatives contact external data source key stakeholders PlatformD  Initial database fingerprinting PlatformD  Data analysis visualization tools including workflow linkage omics data v PlatformD  First EMIFPlatform architecture stack PlatformD  First complete version harmonised information model associated terminology mapping PlatformD  Interim report data linkage PlatformD  Interim report specialised data extraction benchmarking aggregation processing PlatformD  Data analysis tool vertical project v PlatformD  EMIFPlatform version  PlatformD  First draft business plan PlatformD  First report federation procedures ethical legal issues PlatformD  Initial specification semantic framework reference PlatformD  First report EMIFPlatform desing architecture including specification privacy protection tool services PlatformD  Data analysis visualisation tools including workflow linkage omics data v PMOD  Operational portal allow internal team information dissemination team collaboration team document storage PMOD  Technical financial annual report  PMOD  Updated project risk plan WP PMOD  Technical financial annual report  PMOD  Templates dissemination materials logo design ppt poster templates newsletter formats PMOD  Interim assessment project PMOD  Technical financial annual report  PMOD  Communication plan PMOD  Project handbook PMOD  Guidance document EMIF scientific publications PMOD  Operational website internal use external dissemination PMOD  Detailed project risk plan WP content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation EMIF NEWSLETTER MARCH  March  Use button jump article issue Subscribe Newsletter please complete  MARCH   Enduring Success EMIF Platform FAIR Data Collaboration EMIF ADMET Joint GA Meeting Budapest  KEY POINTS success EMIF prof need findable accessible useful data continues grow EMIF IMI created model effectively address need effective data collaboration impact EMIF IMI far reaching highlight need kind initiative CONTRIBUTORS SIMON lovestoneProfessor Translational Neuroscience Oxford University Overall joint program lead EMIF BART VannieuwenhuyseSenior Director RMEDS Real World Evidence Medical Affairs Established Products Statistics Quantitative Sciences Janssen Coordinator overall EMIF project Since IMI began  ha funded many successful program improve healthcare across EU EMIF ha exception accomplishment made EMIF especially    produced proven model collaboration data management medical research so EMIF allowing research happen speed scale wa previously possible say Bart Vannieuwenhuyse Coordinator overall EMIF project Senior Director RMEDS Qualitative Sciences Janssen continue progress EMIF IMI need support Continuing Need Usable Data A Simon Lovestone Professor Translational Neuroscience Oxford University overall joint program lead EMIF reveals one thing EMIF attempting resolve observation make science vast amount data underutilized Technology ha enabled u create store mountain data finding utilizing tends either impossible impractical data exists two forms First electronic health record EHR routine patient care provide huge sample size otherwise unattainable traditional research also indepth observational data collected experience individual patients Second research data ha already delivered value particular project could potentially reused number projects EMIF designed tackle that explains Simon EMIF make data visible provides tool access analyze it includes multiple portals including EMIFAD community second left FAIR Goal B success EMIF initiative ha brought medical research new level making data FAIR Findable Accessible Interpretable Reusable demonstrate this take EMIFAD community EMIF Catalogue ha recently made available public Catalogue EMIF ha made data Alzheimers Disease visible ha also created tool efficiently access use data putting common format ha an enormously difficult task Simon admits Catalogue already demonstrating value far program Europe already made use it including theDPUK theEPAD another program funded IMI Take Action C impact EMIF IMI even made way across Atlantic Ocean  United States law enacted President Obama December  cite IMI successful example emulate important work made possible EMIF need continue Although EMIF itself finite provides successful model future collaborative project Europe world Contact idea extend IMI EMIFs impact rest  beyond MARCH   Building Bridges EMIF Encourages Collaboration Metabolic Research Beyond KEY POINTS Collaboration fields industries sector ha immensely fruitful Sharing data collaboration expert ha allowed researcher take discovery next level Support collaborative effort IMI continue even EMIF begin wind CONTRIBUTORS ULF smithProfessor University Gothenburg Project Lead Metabolic topic DAWN WATERWORTHDirector Genetics Cardiovascular Metabolic Dermatology GSK EFPIA lead Metabolic topic Regardless field EMIF ha vehicle researcher come together way previously feasible effect ha particularly powerful field metabolics via Two influential member metabolics community Ulf Smith Professor University Gothenburg Project Lead Metabolic topic Dawn Waterworth Director Genetics Cardiovascular Metabolic Dermatology GSK EFPIA lead Metabolic topic reveal benefit enhanced level collaboration Collaboration King A meaningful discovery advancement possible researcher dont infrastructure go beyond field Dawn explains order get full value research need seek variety perspectives lesson learned EMIF reach outside discipline says EMIF ha provided unique opportunity researcher across Europe exactly that fact recent recent ha indicated IMI initiative receive among highest citation indexes involve collaboration author across sectors industries nations disciplines Ulf explains researcher gained connection endure even beyond EMIF facilitated ha actually built connection relations says Taking Discoveries Next Level B preEMIF research setting scientist dug deep small cohort identified inspiring possibility projects but Ulf says dont get say yes look promising limited number individuals opportunity work people done indepth research within different infrastructure different populations extremely rewarding says Another rewarding experience truly novel result become possible recent work EMIFMET Ulf cite particularly interesting found mannose circulating biomarker insulin resistance obesityassociated complications could done this without different extremely carefully phenotyped cohort collected EMIF Metabolic topic say Ulf Whats more beginning large followup study submitted shortly identified mannose predicts future type two diabetes cardiovascular disease adds  deidentified patient record across Europe available researcher look development metabolic disease time focus intervention individual high risk enables researcher test validate translate new idea valuable concept potentially useful area like disease development therapy EMIF IMI make possible derive new insight research Whats Next C EMIF ha produced important work which need maintained implores Ulf professional relationship cultivated EMIF continue even EMIF begin wind down scientist genetics like Dawn might wide network within field genetics EMIF IMI broaden reach says adding that allows better expansive science end day collaboration need continue whether supporting new IMI initiatives broadening professional networks Left image EMIFMetabolic Project Achievements Take Action D Keep contact made within EMIF continue take advantage networking opportunity push outside field sector connection make ensure continue press forward science community develop innovation research Contact collaborate network withinor beyondthe field metabolic disease MARCH   Reuse Reconvening Data Sharing Networking Alzheimers Disease Research KEY POINTS benefit reusing data EMIF project undeniable Bringing diversity healthcare perspective together ha yielded wonderful unforeseen result tool developed IMI great help people make happen CONTRIBUTORS PIETER JELLE VISSERAssociate Professor Maastricht University VU University Medical Center Project Lead AD topic JOHANNES STREFFERDirector Experimental Medicine Janssen EFPIA lead AD topic Medical researcher Europe looking thing new way thanks EMIFs powerful new infrastructure collaboration Associate Professor Pieter Jelle Visser Maastricht University VU University Medical Center Johannes Streffer Director Experimental Medicine Janssen leader within Alzheimers disease AD topic EMIF represent collaboration academia industry one core achievement EMIF initiative insight success shed light path ahead well Rewards Reuse A new infrastructure collaboration provided EMIF ha already proven valuable tool searching treatment associated AD especially impact society continues grow major disorder huge social economic impact treatment yet explains Pieter Jelle lack knowledge make infrastructure created EMIF especially important disorder like AD allows u reuse data ha already collected significantly lowering time cost required conduct research One example  cohort  subjects worldwide wa conducted recently took two years But Pieter Jelle added collected  subjects scratch would cost around  million Euros would taken something like  years Left image EMIFAD Project Achievements Everyone One Table B Another major benefit created EMIFAD ha getting industry academia one table aligning goals say Johannes ha also fostered collaboration different representative Pharma industry even researcher completely different field would never incentive before One benefit bringing many party together allows u get know one anothers perspectives Pieter Jelle explains example field metabolics often focus metabolic disorder affect obesity mortality he person working AD research interested disorder could affect brain left right Suzanne Craft Simon Lovestone Hilkka Soininen Ulf Smith panel theEMIF ADMET joint meeting Budapest March  Take Action C Pieter Jelle Johannes passionate one topic particular work done within EMIFAD IMI continues infrastructure technology used connect medical research community Europe ha wonderful collaborative tool technological platform Johannes insists that beyond technology involved EMIF collaborative spirit ha prevalent need endure take success EMIF next level AD research beyond Keep touch connection youve made EMIF reach outside current research community develop new relationships Contact idea working across field sharing data support AD research MARCH   Human Side Big Data EMIFPLAT Paving New Roads Medical Research KEY POINTS Despite initial challenges EMIFPLAT proving worth exceeding expectation EMIFPLAT isnt changing technology changing society Harmonization possible data people CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIFPLAT Janssen Pharma RD JOHAN VAN DER LEIAcademic Coordinator EMIFPLAT Professor Erasmus University inception EMIF Platform  team worked overcome technical societal hurdles constant evolution refinement created platform created new way conceiving whats possible shared data medical science Already result work validatingand inspiring Nigel Hughes EFPIA Coordinator EMIFPLAT Janssen RD Johan Van Der Lei Academic Coordinator EMIFPLAT Professor Erasmus University agree human le measurable output among powerful collaborative spirit brought many great people together EMIF become essential solving challenging healthcare quality life issue time Building Plane Flying Plane A first decided merge   PLAT project within EMIF proposal five year ago task data harmonization wa met degree skepticism Data wa hand many different people organizations disparate way storing managing it tackle that learning go building learning say Nigel learning ha open source technology help systematize standardize data collection storage learning ha around value crossfield even crossproject collaboration fact EMIFAD EMIFMET EMIFPLAT shouldnt cant exist separate projects say Nigel Although independent work sometimes necessary increasingly second half EMIF project decision made based dialogue projects example platform wa conceived created time Alzheimers metabolic team expressing needed platform wa like trying fly plane youre still building it reveals Nigel beauty simultaneous process wa EMIFPLAT team built real people real project need Left Image detailed architectural view reveals two paths population cohort learn technical aspect EMIFPLAT contact  tune next issue EMIF Newsletter Proven Need B One early win EMIFPLAT wa ability vastly improve speed people identify data sources systematised metadata driven listing data source within EMIF January  EMIF Data Catalogue wa released beyond EMIF community le two months  bonafide researcher already signed explore  population data source  EMIFAD cohorts plan coming year Johan says expand capability researcher evaluate suitability ultimately conduct study data source collaborators available bonafide researcher outside EMIF Long Winding Road C many ways bump road building EMIFPLAT human technological sociotechnical issue something may heard youve ever spoken Johan Yes data one zeroes end day people health data managed universities governments payers mean access also relationships laws intended use data Ultimately gaining trust say Nigel that people need see something works Guess What Works D greatest legacy EMIFPLAT certainly harmonization already many example harmonizing data vastly improves usability research partnership Observational Health Data Sciences Informatics  collaboration EMIFPLAT also focus human harmonization powerful tool available overcome pressing human challenges medical otherwise one another EMIFPLAT already proving whats possible beginning Take Action E need strive meaningful collaborations EMIFPLAT team look forward collaborating project IMI IMI others well partner across industries companies fields sectors whether public private need continue pushing open source technology open source idea support open science Instead withholding lesson learned Nigel Johan want share them Whether youre architect bioinformatics expert ethicist contact youd like learn social technical aspect EMIFPLAT youd like share idea harmonization ensure legacy EMIFPLAT life on MARCH   Big Data Big Goals IMI Projects Lead Way Harnessing Power Big Data KEY POINTS IMI ha already demonstrated value big data several successful project Look new project coming IMI continue work toward goal Despite legal logistical difficulties value big data undeniable CONTRIBUTORS PIERRE MEULIENExecutive Director Innovative Medicines Initiative Big data analysis hold enormous potential acquiring new actionable medical knowledge increasing availability database containing medical research data combined growing analytic capability could lead better treatment improved outcome patients world largest publicprivate partnership life sciences perfectly placed harness potential lay groundwork reuse clinical data Europe History Success A Several IMI project already working towards goal good example one IMIs older big data projects  started  connecting electronic health record  different hospital across Europe project created platform help researcher design clinical study recruit patient participate them platform connect securely anonymized data within multiple hospital electronic health record system clinical data warehouse across Europe enabling researcher predict number eligible patient candidate clinical trial protocol also help ass feasibility trial locate relevant hospital site recruiting patients Another IMI project field  focus improving translation data preclinical clinical studies service project us open source tool tranSMART provide access different type biological clinical data wellstructured environment project place special emphasis data cleaning standardization deliver high data quality improve crossstudy compatibility  project already benefited services Among eTRIKSs achievement creation  unique repository contains description IMI project databases catalogue making easier researcher find information clinical datasets may available reuse then course EMIF IMI project using power big data solve riddle two big healthcare challenge time metabolic disorder Alzheimers disease order improve understanding diseases EMIF team connecting multitude relevant data source across Europe process theyre addressing number data issues including data standards semantic interoperability ethics data privacy legal issues project also developing platform allow access multiple data source done finished may interlink data  million adult across Europe Horizon B Looking toward future new IMI project field starting part IMIs Big Data Better Outcomes BDBO program launched  program aim facilitate use diverse data source deliver outcome measure treatment meaningful patients clinicians regulators researchers others Diseasespecific project addressing Alzheimers disease  blood cancer  already started project cardiovascular disease launched soon project look available clinical data multitude sources disease areas combine standardize analyze data obtain relevant outcome measures Part program also newly launched IMI project called DOIT Rather focusing specific disease area project aim generalize result BDBO project disease areas One main deliverable generic informed consent form template participant clinical trials language form formulated way allow clinical data reused research purposes project aim disseminate form among researcher companies used widely possible Apart project work issue directly IMI want instil good data practice projects Prior starting project required fill  encourages team think early collecting storing data according good standards idea course ensure data generated IMI project potentially combined data generated elsewhere analyzed bigger scale Take Action C move increasingly digital environment healthcare also society big data become major determinant future medicine shaped publicprivate partnership involving multitude stakeholders IMI project leading way field creating framework data across Europe could shared easily success IMI project field ha potential persuade data holder across Europe legal logistical obstacle clinical data reuse overcome greater benefit patients Contact find aboutand get involved inthe continuing effort IMI content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation EMIF NEWSLETTER JUNE  June Use button jump article issue Subscribe Newsletter please complete  JUNE   Power Harmonization EMIF Enables LargeScale Analytics Embracing OMOP Common Data Model EMIF currently mapping European data source OMOP CDM extending OHDSI tool  order properly answer biggest research question timeincluding would help u solve mystery Alzheimers disease metabolic diseaseswe need ass large amount data fully transparent reproducible way Standardization data structure language Common Data Model CDM enables unprecedented scale KEY POINTS Data harmonization process translating data common format common vocabulary enable collaborative research largescale analytics European Medical Information Framework EMIF ha core objective building information framework consistent reuse available patientlevel data support novel research Observational Health Data Sciences Informatics OHDSI collaborative work toward international implementation OMOP Common Data Model CDM standardized vocabularies EMIF currently mapping European data source OMOP CDM extending OHDSI tool enable largescale analytics key EMIFs core objectives CONTRIBUTORS MICHEL Van SpeybroeckDirector Data Sciences Janssen PETER Rijnbeek PhDAssistant Professor Erasmus University Medical Center JOHAN van der LeiAcademic Coordinator EMIFPLAT Professor Erasmus University Medical Center Big Healthcare Data A Every moment countless healthcare data point generated stored digital database across Europe Analyzing datasets challenge data structure content vary greatly one healthcare organization next Data collected different purposes clinical research patient care payer reimbursement more mean content level detail varies considerably Datasets stored different format using different database management systems Moreover different code used medical concept across Europe creates additional challenges overcome overwhelming barrier performing multidatabase study across Europe beyond EMIF Rises Challenge B recognized challenge day one Standardization wa initially done context specific research question limited set variables However EMIF realized approach wa difficult maintain answering research question large scale substantial upfront standardization effort would necessary scalability Additionally study needed performed distributive manner comply governance privacy rule keeping standardized datasets within local infrastructures shared analytical datasets needed generated using standardized processing pipeline Odyssey Toward Harmonization C EMIF found solution challenge embracing OHDSI pronounced Odyssey model translating data single common structure language concept known data harmonization also sometimes called data standardization representing process data harmonization using OMOP Common Data Model  publicprivate partnership originally established US OMOP project developed initial version  accommodate healthcare data diverse source consistent standardized way OHDSIs mission improve health empowering community collaboratively generate evidence promotes better health decision better care key objective stimulate transparent reproducible research CDM prerequisite Today OHDSI international collaborative comprised academics industry scientists healthcare providers regulator come together create apply opensource data analytic solution large network health databases nonfunded entity supported generosity passion individual member well inkind contribution organization Columbia University Johnson  Johnson inspiring spirit global collaboration power OHDSI EMIF Common Data Model d many reasons OMOP CDM welladopted model covering  million patient life worldwide code tool open source publicly available stimulates collaborative tool improvement transparency Moreover currently available tool fit naturally EMIFs objective facilitate different level data access Workflow map EMIF EHR data source OMOP CDM leveraging OHDSI tool experience CDM widely used US Asia beginning scratch surface use Europe EMIF helping prototype CDM European continent example exploring whether level detail European Electronic Health Records EHR would lost translated data CDM peer fellow collaborator OHDSI constantly adjusting CDM vocabulary accommodate type insights CDM also evolving healthcare evolves OMOP Common Data Model expands continents countries disease areas CDM expands thanks collaboration OHDSI champion around globe Calling Data Custodians F EMIF want actively support adoption OMOP CDM across Europe data custodian Europe want participate innovative data network contact   learn more mapping data doe require time commitment EMIF available help Additionally ODHSI website offered freetoattend OHDSI symposia Documents best practice converting data OMOP CDM available  clear advantage adopting ODHSI EMIF working on Thanks multidisciplinary expertise OHDSI community quality functionality tool constantly improved process open source start finish license ever needed Perhaps importantly data privacy concern respected keeping data local implementing CDM yourself Even EMIF provide support technical side process data still kept locally Youll able maintain privacy database contributing worldwide effort harmonize data decision map database CDM mean supporting progress reproducible scientific research local national international level Next Steps EMIF G EMIF actively mapping nine European data source OMOP CDM OHDSI vocabularies Denmark AUH Italy ARS IMS HEALTH LPD PEDIANET Spain IMASIS SIDIAP UK THIN Estonia EGCUT Netherlands IPCI PHARMO EMIF produce scientific paper year evaluates mapping process European datasets formulates suggestion improving CDM vocabularies Furthermore EMIF continue effort extending refining OHDSI tool meet objectives want data analysis unprecedented scale along fully transparent reproducible research pipelines need collectively harmonize data structure terminology OMOP CDM clearly becoming de facto standard electronic health data across world EMIF recognizes exciting new reality stakeholder benefit researchers organizations importantly patientswho ultimately center global effort researcher want explore more please visit  data custodian interested learning OMOPCDM data source contact    JUNE   Knowledge Comes Responsibility Harmonizing Cohort Data EMIFAD European Medical Information Framework Alzheimers Disease EMIFAD Work Package WP  team members left right Pieter Jelle Visser Stephanie Vos Isabelle Bos  researcher Simon Lovestone Pieter Jelle Visser Johannes Streffer led team identify potential fluid marker brain amyloid small study cognitively normal people wanted confirm finding sample  individuals didnt resource assemble large cohort de novo Luckily one EMIFs objective make possible reuse data instead generating new data single purpose Electronic Health Record EHR data standardized  however cohort data another solution wa necessary KEY POINTS European Medical Information Framework EMIF Catalogue allows user quickly complete new research identifying cohort via EMIF Alzheimers disease EMIFAD community Analyses large pooled datasets made possible technical team developed idea using knowledge object purpose data harmonization EMIFAD team invite data custodian researcher provide metadata cohort share data research question help crack dementia code CONTRIBUTORS RUDI VerbeeckSenior Manager Janssen RD ISABELLE BosNeuropsychologist PhD Candidate Maastricht University LUIZA GabrielZeltzerPostdoctoral Researcher Janssen RD STEPHANIE VosNeuropsychologist Postdoctoral Researcher Maastricht University PIETER Jelle VisserAssociate Professor Maastricht University VU University Medical Center Project Lead AD topic Biomarker Discovery Study A Within EMIFAD project divided work package WPs WP  focus definition study population data requirement data collection Members EMIFAD WP  team Pieter Jelle Visser Stephanie Vos Isabelle Bos consulted AD community online community existing cohort maintained EMIFAD identified  suitable cohort participant characteristic researcher looking term age sex cognitive status amyloid biomarkers cerebrospinal fluid CSF positron imaging tomography PET availability MRI scan fluid sample plasma CSF EMIFAD WP  team contacted principal investigator cohort interested participate Contracts setup allow datasharing biomarker analysis Data source owner harmonizedor translatedtheir local variable global set variable data could used study way large cohort wa assembled quickly inexpensively final Biomarker Discovery Study included  subjects data combined proteomics genomics metabolomics imaging data single analysis broad spectrum analysis large cohort subject various cognitive stage provide new insight underlying mechanism facilitate discovery new diagnostic prognostic marker AD study coordinated Simon Lovestone Johannes Streffer Pieter Jelle Visser close collaboration proteomics metabolomics transcriptomics genomics bioinformatics imaging expert EMIFAD Translating Language Science B Biomarker Discovery Study analysis large cohort made possible collaboration EMIFAD researcher EMIFPlatform technical team developed idea using knowledge object purpose data harmonization knowledge object variable plus information need order correctly interpret variable means instance sex knowledge object included Biomarker Discovery Study male female common value knowledge object Diagram envisioning process data harmonization mapping local knowledge object global knowledge objects Data source appear left harmonized data appears right EMIFAD researcher gathered data  different study assemble EMIFAD WP  cohort different language none used exactly standard recording variables tried access original data data sources variable sex might appeared genero geschlecht obscure variable may difficult interpret impossible translate similar datasets without common reference point Thats Rudi Verbeeck Senior Manager Janssen RD EMIF contributor belief cohort data custodian play crucial role quest aggregate data data custodian know variable data source truly represent Thanks EMIFPlatform team custodian power define local variable data translated standard set global variables Knowledge Responsibility C knowledge responsibility explains Rudi Data custodian knowledge data responsible defining local variables Researchers know point data support research responsible identifying variable want access brings together knowledge data custodian knowledge researcher data harmonized large cohort analyzed Isabelle Bos Stephanie Vos neuropsychologists researcher Maastricht University member EMIFAD WP  team Theyve chosen take responsibility helping data custodian translate local knowledge object global knowledge objects data custodian dont technical skill map data themselves data custodian specifies mapping done EMIFAD WP  team creates code need executed currently  cohort data platform across Europe Netherlands UK Belgium Spain Italy Sweden France Greece total number subject across  cohort  number keep growing Local knowledge object LKO appear left side semantic dependency graph local knowledge object translated global knowledge object GKO using snippet code represented arrows Sometimes onetoone correlation local knowledge object global knowledge object times multiple local knowledge object feed single global knowledge object series standardizing equations Building Library D time EMIFPlatform continue building library reusable knowledge object snippet code connect them researcher make request EMIF Catalogue AD community variable havent used before knowledge object need mapped data custodian support EMIFAD WP  team Since every research question add library probability able reuse knowledge object snippet code increase every research question come along Common Goal E order tackle biggest health challenge time researcher must able conduct efficient costeffective data analysis large scale that necessity cohort  subjects cant answer complex research questionsbut increase cohort  may uncover kind exciting result EMIFAD group collaborator seeing Biomarker Discovery Study harmonize data need shared cohortderived dataespecially includes biomarkersand would like collaborate please consider working EMIFPlatform team harmonize data using knowledge objects Harmonized cohort data could lead breakthrough fight Alzheimers researcher explore data source already available AD EHR communities made publicly available bona fide researcher outside EMIF January  Every day new people around world join  user accessed Data Catalogue work toward research goals could assemble huge cohort quickly inexpensively kind study would create discovery might spearhead EMIF want know want help make happen JUNE   Introducing Use Case  Using Electronic Health Record Data Understand Relationship Dementia Inflammation Oxford University research team exploring link dementia inflammatory diseases medical science research community pondering relationship dementia inflammatory diseases Alejo J NevadoHolgado Danielle Newby postdoctoral researcher University Oxford exploring link depth found asking inflammatory diseasesor drug used treat themchange risk dementia later life compelling research question set stage Use Case  project underway within the KEY POINTS analyzing electronic health record EHR data European Medical Information Framework EMIF platform find link inflammation dementia Use Case  utilizing EMIFs visible accessible harmonized datasets complete groundbreaking research whether inflammatory disease drug used treat change risk dementia later life Later  look published information likely assist development therapy treatment dementia CONTRIBUTORS DANIELLE NEWBYPostdoctoral researcher University Oxford Data analyst Use Case  ALEJO NEVADOHOLGADOSenior postdoctoral researcher University Oxford Lead Use Case  project SIMON LOVEStoneProfessor Translational Neuroscience University Oxford Overall joint program lead EMIF Challenges Solutions A motivated team Oxford wa curious relationship inflammatory diseases antiinflammatory drugs dementia saw exiting opportunity work large realworld routine care datasets realized study challenging perform one thing large datasets needed analysis another research study cohort suffer selection always fully representative large datasets accessible Danielle emphasizes another challenge present itself tough get consistent datasets due different structure electronic health record HER different countries EMIF provided opportunity overcome problem making datasets visible   Use Case  Oxford team examining relationship disease inflammation drug used treat inflammatory disorder multiple datasets work theyre revealing stronger evidence relationship dementia inflammatory exposures team groundbreaking research set example others researcher may excited learn question like posed within Use Case  analyzed answered efficiently working EMIF Start Finish B start Use Case  team needed good question could potentially answered using EHR data hypothesis relating inflammation dementia protocol underwent ethical peer review expert field next step wa contact data custodian responsible datasets  able participate joined Use Case  team asked data custodian extract variable needed anonymized patient level record database place secure remote research environment Daniel PrietoAlhambra scientific coordinator SIDIAP database wa enthusiastic contributing SIDIAP database Use Case  stating inclusion SIDIAP dataset Use Case  offer great opportunity utilize wealth information database help understand important topic quality control check datasets local database expert started work dataset ran software tool aggregated file dataset removed outliers selected sample population based criterion specified original protocol Thanks seamless collaboration EMIFPlatform team data dataset stage wa ready statistical analysis Workflow Use Case  Now C Use Case  cusp exciting phase data analysis Nearly datasets extracted almost ready analyzed team built clever step process analyzing one dataset first run preliminary check help troubleshoot analysis rest datasets Alejo confirms participating Use Case  ha excellent learning experience team come opportunity challenge analysis across multiple realworld datasets fortunate good help expertise guide u move work forward successfully Danielle reports Later  look publication finding datasets Use Case  team belief result could lead meaningful advancement treatment Alzheimers disease dementia Take Action D perfect example successful collaboration data sharing among researcher data custodians idea think could answered using EHR data progress Use Case  give confidence robust analysis possible would like learn get involved continuing progress Use Case  contact collaborate network welcome ideas help expertise anyone within EMIF interested involved dementia research Danielle speaking behalf Use Case  team says want collaborate share knowledge make even greater progress toward ultimate goal development new therapy treatment dementia reading determining molecular pathway underlying protective effect nonsteroidal antiinflammatory drug Alzheimers Disease please see Alejo Simons October   JUNE   Precompetitive Research MultiDisciplinary Team Investigation NonAlcoholic Fatty Liver Disease Recorded Primary Care Databases crosscompany team discovered heterogeneity prevalence recorded nonalcoholic fatty liver disease European databases diverse team come together tackle research question rising epidemic metabolic disorders Theproject make possible NonAlcoholic Fatty Liver Disease Electronic Health Record NAFLDEHR team subset EMIFMetabolic team composed member pharmaceutical industry academia background ranging epidemiology genetics medicine statistics member expertise cardiovascular disease hepatology others deep knowledge healthcare databases scattered around globe mainly located Europe would chance come together without infrastructure EMIF within the KEY POINTS European Medical Information Framework EMIF enables collaboration partner pharmaceutical industry academia EMIF collaborator conduct precompetitive research multiple European database unified environment EMIF enables pharmaceutical industry unprecedented access routinely recorded European healthcare data respecting appropriate security ethic provisions crosscompany team discovered heterogeneity prevalence recorded nonalcoholic fatty liver disease European databases well low detection rate primary care CONTRIBUTORS MYRIAM ALEXANDERClinical data scientist analyst GlaxoSmithKline NAVEED SATTARProfessor Metabolic Medicine University Glasgow DAWN Waterworth Genetics Director GlaxoSmithKline KATRINA loomisHead Cardiovascular Metabolic Disease Human Genetics Pfizer WILLIAM alazawiSenior lecturer Consultant Hepatology Blizard Institute Barts London School Medicine JOLYON fairburnbeechData analyst GlaxoSmithKline Motivating Questions A Prior collaborating u wa motivated answer key question epidemiology nonalcoholic fatty liver disease NAFLD as prevalence incidence disease primary care data NAFLD associated increased risk cardiovascular disease accounting risk factor may potentially confound association excess risk NAFLD patient experience come developing liver complications including cirrhosis hepatocellular carcinoma question remained difficult answer without access large sample patient extensive medical data Fortunately opportunity work within EMIF Unprecedented Access B Via EMIF access unprecedented largescale database collected routinely primary care system four European countries UK Netherlands Catalonia region Spain Italy identified suitable database using EHR community used support EMIF contact data custodian project partners Attrition demographic characteristic patient NAFLD four European databases Harmonizing Data C Use Case  team developed protocol submitted ethical review body database upon approval single finalized protocol wa circulated parties four database used different terminology system code clinical diagnoses process data harmonization wa needed enable team create comparable lists protocol wa translated series data management statistical analysis steps data wa locally extracted data custodian centrally analyzed remote server New Level Trust D Thanks EMIF pharma company involved project able accessfor first timean anonymized subset raw data databases there company able perform analyses plumbing depth various databases ha enabled party experience new level trust efficient reuse routine data benefit bona fide research First Results E analysis data analyst GlaxoSmithKline GSK ongoing latebreaking abstract wa presented incidence prevalence NAFLD Data available  million adult  year followup registration  individual diagnosis NAFLD nonalcoholic steatohepatitis NASH amounting pooled prevalence  January  Although relatively low compared prevalence estimate literature   NAFLD general population patient characteristic line literature Incidence recorded NAFLD per  personyears  four countries pooled across countries PointPrevalence recorded NAFLD per  persons  four countries pooled across countries Next Steps F sample NAFLD patient represents largest NAFLD cohort ever assembled enable research NAFLD interest pharmaceutical industry field medicine team especially excited potential research may answer motivating question mentioned above want know NAFLD associated increased risk cardiovascular disease accounting risk factor may potentially confound association also want know excess risk NAFLD patient experience come developing liver complications Progression NAFLD NASH beyond source Decision Resources youre field metabolics want learn study findings contact  JUNE   Milestone Meeting EMIFPlatforms th Consortium Meeting EMIFPlatform colleague gathered Barcelona May   th Consortium Meeting EMIFPlatform January  theIMI world largest publicprivate partnership life sciences began funding landmark initiative TheEMIF wa launched ground breaking fiveyear project develop technical governance solution improve access use health data  mark EMIFs fifth final year funding IMI go accomplished far KEY POINTS exciting th Consortium Meeting European Medical Information Framework EMIF Platform took placein Barcelona May   Important milestone discussed including technology platform data harmonization sustainability research use cases expedited research efficiency publication strategy EMIF making significant contribution field real world data health research work remains done final year Innovative Medicines Initiative IMI project CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIFPLAT Janssen Pharma RD past four years EMIF made considerable progress developed integrated platform facilitate access diverse medical research data source across Europe sustainable framework support identification assessment use reuse health data medical research guide development information framework IMI originally selected two therapeutic area critically important juncture history Alzheimers disease EMIFAD metabolic disease EMIFMetabolic pressing research topic provided EMIFPlatform clear opportunity support researcher technological tool governance processes Thanks EMIFPlatform team researcher EMIFAD EMIFMetabolic working address world biggest health challenges Meeting Minds A Since EMIFAD EMIFMetabolic leverage framework created EMIFPlatform one could say EMIFPlatform bedrock EMIF Thats approximately  EMIF colleague met Barcelona th Consortium Meeting  May    EMIFPlatform team shared milestones recognized progress discussed work horizon rest year Six major theme emerged Theme  Technology Platform B first time fouryear history EMIF integrated platform wa presented outline form see figure  evaluating integrated platform rest year visualization major achievement EMIF integrated platform allows researcher access  specify parameter data fit research questions analyze data secure private remote research environment PRRE technological development mean researcher able analyze large datasets still respecting data privacy Figure  Integrated EMIF Platform Theme  Data Harmonization C EMIFPlatform ha helped European continent advance towards data harmonization continue map population data source CDM EMIFPlatform team working hard make sure data custodian colleague comfortable mapping conversion process EMIFPlatform team also offering support data custodian use OHDSI mapping data CDM Simultaneously making progress assembling cohort data EMIFAD variable translate data local global vocabulariesallow u add AD cohort EMIF Catalogue AD community knowledge object team similarly support data owner researcher add access relevant cohort data Theme  Sustainability D EMIFs goal create sustainable technology governance framework identification assessment use reuse health data medical research Europe Weve spent past four year developing technology governance framework Now increasing focus sustainability weve made progress toward developing potential sustainability model population cohort tracks much work needed end year need clear plan implement EMIFs proposed extension first half  Theme  Research Use Cases E th EMIFPlatform Consortium Meeting colleague shared progress many use case see figure  come fruition later year Invaluable insight use case help EMIF better understand research process well potential challenge researcher data custodian face Stay tuned use caseslike documented shared Figure  EMIFPlatform Research Use Cases currently running Theme  Expediting Research Efficiency F Deeper insight research processespecially come bottleneck potential solutionswill enable EMIF manage research efficiently Insights current use case proposed study allow u pressure test operational feasibility helping u evaluate EMIFPlatform architecture scientific research perspective Theme  Publication Strategy G EMIFPlatform consortium also focused prioritizing publication remainder project Within remainder IMI program plan promote external publication EMIFs technological methodological scientific activities need ensure research community large becomes familiar EMIF developments invite interested party  Progress Future Work H discussion th EMIFPlatform consortium revealed work limited time remains also recognize EMIF ha made significant contribution field real world data health research work past four year ha proven critical sustainable integrated platform diverse data source collaborations based harmonized approach federated network model partner collaborator rightfully proud achievements focus energy need done rest  must create operational model sustain European medical research via real world data  beyond would like support future EMIF please contact  content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation EMIF NEWSLETTER NOVEMBER  November Use button jump article issue Subscribe Newsletter please complete  NOVEMBER   Improving Access Human Health Data EMIFs Commitment Collaboration EMIF ha made great progress several area   EMIF wa launched IMI January  high hope fiveyear project wanted increase access human health data improving life science research bringing better safer medicine patients IMIfunded phase EMIF project drawing close June  wed like take opportunity reflect journey KEY POINTS Innovative Medicines Initiative IMI funded phase EMIF project come close end June  past five years EMIF ha facilitated collaboration make major breakthrough tool development cohort development biomarker discovery EMIF team member wrapping existing project also working create sustainable environment collaboration continue flourish CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIFPLAT Janssen Pharma RD Collaboration Key A goal wa monumental knew could make progress collaborating past five year  EMIF ha brought together academic centre excellence subject matter experts industry giants patient organization combined  partner across  European country  million worth resources focusing three major projects Collaboration grand scale ha made EMIFs achievement possible Major Projects Achievements B progress toward EMIFs goal developed framework  evaluating enhancing providing access human health data across Europe help guide development EMIFPlatform chose two pressing area therapeutic research onset Alzheimers disease  metabolic complication obesity  achievement past five year even greater initially hoped hosted iHD EMIF Professor Dipak Kalra President iHD introduced EMIF follows wanted example best big data medicine EMIF would it three project area made major breakthrough tool development cohort development biomarker discovery shared discovery around world including  scientific publication published  public presentation orated EMIF  poster presented conference  August  Speaking collaboration conferences pleased working Erasmus Medical Centre development OHDSI European Union EU Chapter first annual scheduled  Erasmus Medical Centre Rotterdam Netherlands Collaborations organization OHDSI ensure EMIFs mission continue even IMIfunded phase EMIF project concluded Looking Future C phase project wrapping up doe mean stop striving increased access human health data fact find need growing time countless potential application real world data drug development discovery development launch postlaunch always need improving life science research bringing better safer medicine patients Potential application real world data drug development EMIF wrap existing projects also working create sustainable environment collaboration continue flourish th final December   Barcelona focus celebrating achievement ensuring sustainability proud work EMIF ha accomplished date cannot wait see lead future Contact information continuing collaborate future NOVEMBER   Realizing Value Health Data  Joint Meeting Hosted iHD EMIF Madrid September    iHD EMIF hosted joint meeting Hospital Universitario  de Octubre Madrid Spain September    iHD EMIF hosted joint meeting Realizing Value Health Data Improving Care Research Well  delegate attended meeting took place Hospital Universitario  de Octubre Madrid Spain KEY POINTS  delegate attended September joint meeting hosted European Institute Innovation Health Data iHD European Medical Information Framework EMIF Madrid Spain meeting focused value reusing clinical data improving health care clinical research Multiple presenter panellist highlighted important role trust reusing health data CONTRIBUTORS JELLE PRAET PhD Project Manager Janssen Pharmaceutica Reusing Clinical Data A first day meeting wa hosted iHD kickoff session representative Spanish Estonian health ministry elaborated importance reusing clinical data improving health care clinical research addition emphasized need dialogue patients explained essential tell patient result achieved allowing reuse data Representatives Spanish Estonian health ministry elaborate importance reusing clinical data improving health care clinical research Trust B remainder morning goal challenge transition toward valuebased outcomesbased health care discussed Mary Baker chairperson session stated stop talking cost health care start talking investment health long run second half day examined empowerment patients integral aspect patient empowerment development solution lead healthy data ecosystem ecosystem must quality data also place high priority trust mutual trust bona fide reuse data utmost importance advance field patient representative put it end trust EMIF Takes Stage C EMIFAD Project Achievements second day meeting EMIF project took stage Professor Dipak Kalra President iHD introduced EMIF follows wanted example best big data medicine EMIF would it day started overview EMIFs achievement building using EMIF platform also applying tool field Alzheimers obesity past five years EMIF ha developing common technology governance framework addition EMIF ha creating online platform identification assessment access reuse health data across academia industry payers governments EMIF ha two disease focus evaluate frameworkEMIFAD andEMIFMET Researchers working apply EMIFs tool technology identify novel biomarkers Alzheimers metabolic diseases EMIFAD EMIFMET made significant achievements EMIFMET Project Achievements Greater Benefit Patients D Throughout day presenter spoke many different aspect reuse health data discussing audience Among aspect discussed technical ones harmonization electronic health record data via collaboration  OHDSI Presenters also spoke harmonization AD cohort data Switchbox common data model wa developed within EMIF specifically purpose Additionally presenter raised many nontechnical aspect regard governance expansion data source collaborations sustainability legacy EMIF elements Bart Vannieuwenhuyse EMIF Coordinator Senior Director Janssen Pharmaceutica speaks attendee second day joint meeting day ended panel discussion Panel member asked hoped would legacy EMIF Michel van Speybroeck Janssen Data Sciences replied ultimate objective work put result improved health outcome everyone hope succeeded laying foundation data ecosystem health data reused good trust greater benefit patients Nigel Hughes EMIFPlatform CoCoordinator Janssen Pharma RD added final thought Michels saying  bioinformatics humans data itself Professor Sir Simon Lovestone EMIF CoCoordinator professor translational neuroscience Oxford agreed get patient partner involved trust other couple endless ambition really make difference patient lives NOVEMBER   Bridging Europe First Annual European OHDSI Symposium Scheduled March  First Annual European OHDSI Symposium take place Rotterdam March  EMIF project main objective develop sustainable platform enables data discovery unprecedented use data source wide variety types including Electronic Health Records EHR primary hospital care challenging task data source ha underlying data model make use common tool difficult extraction process le transparent Differences clinical terminology system complicate study across European data sources KEY POINTS European Medical Information Framework EMIF ha adopted Observational Medical Outcome Partnership Common Data Model OMOPCDM developed Observational Health Data Sciences Informatics OHDSI Initiative standardize European data source common structure language EMIF working Erasmus Medical Centre develop European OHDSI Chapter first annual March   Erasmus Medical Centre Rotterdam Netherlands CONTRIBUTORS PETER RIJNBEEK Assistant Professor Department Medical Informatics Erasmus University Medical Centre Data Standardization Rescue A EMIF overcome challenge embracing OHDSI pronounced Odyssey model translating data common structure language might recognize conceptits known data standardization EMIF mapping European data source common data model developed OHDSI also extending OHDSI tool enable largescale analytics key EMIFs core objectives Origins OHDSI B  publicprivate partnership originally established United States OMOP project developed initial version OMOPCDM accommodate health data diverse source consistent standardized way OHDSIs mission improve health empowering community collaboratively generate evidence promotes better health decision better care key objective stimulate transparent reproducible research OMOPCDM prerequisite Today OHDSI international collaborative comprised academics industry scientists healthcare providers regulator come together create apply opensource data analytic solution large network health databases nonfunded entity supported generosity passion individual member well inkind contribution many organizations OHDSI powered spirit global collaboration New Chapter OHDSI C EMIF pleased working Erasmus Medical Centre development European OHDSI Chapter first annual scheduled March   Erasmus Medical Centre Rotterdam Netherlands Erasmus Medical Centre Rotterdam host first annual European OHDSI Symposium source  symposium called Bridging Europe aim establish European community actively contributes global OHDSI mission symposium participant share result idea use OMOPCDM tool development future research studies meeting feature collaborator showcase involving poster session highlight OHDSIs research achievement interactive demonstration OHDSIs opensource software tools Standardizing European health data enable distributed research study unprecedented scale say Dr Peter Rijnbeek Assistant Professor Department Medical Informatics Erasmus University Medical Centre annual OHDSI symposium perfect instrument stimulate support transition Join exciting journey Register D active participant EMIFs work utilizing OMOPCDM new OHDSI interested learning exciting initiative Whatever level experience welcome Registration limited  participants please soon possible reserve spot NOVEMBER   Celebrating Achievements Ensuring Sustainability th Final EMIFPlatform Consortium Meeting EMIFPlatform infrastructure Electronic Health Records EHRs past five year EMIF project EMIFPLAT worked closely many colleagues including University Aveiro Portugal Together developed integrated platform facilitate access diverse medical research data source across Europe sustainable framework support identification assessment use reuse health data medical research Two track EMIF architecture support two data types Electronic Health Records include routine healthcare data general practice hospitals cohort datasets include data specific research communities KEY POINTS European Medical Information Framework EMIF Platform community gather final consortium meeting December   meeting focus learning Use Cases might taken consideration final Platform Another topic meeting sustainability including publication strategy business planning legacy EMIF need work inclusively progress sustainable element continue beyond Innovative Medicines Initiative IMIfunded phase project CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIFPLAT Janssen Pharma RD Looking Forward A Barcelona May  many important milestone discussed including technology platform data harmonization sustainability research use cases expedited research efficiency publication strategy EMIFPLAT community gather final consortium meeting December   th final consortium meeting member evaluate progress date well discus final activity end project Jun  th meeting likely reflect one wellknown achievements going public January   user registered EHR community Catalogue Since January  continued work data harmonization electronic health record data custodian via  ha involved work evaluating data fidelity EMIF Catalogue homepage EMIFs collaboration OHDSI ha made much data harmonization work possible pleased working Erasmus Medical Centre development OHDSI European Union EU Chapter first annual scheduled March   Erasmus Medical Centre Rotterdam Netherlands Onboarding New Cohorts B th meeting also evaluate work additional EMIFAD cohorts Using Switchbox common data model onboarded cohort EMIFPlatform onboarding new cohorts make sure populate participant variable selection tools tool allow researcher identify subsamples individual subset variable fit need research questions work support establishment EMIFAD platform sustainable infrastructure crucial AD research Europe Expedited Research Efficiency C consortium meeting explore manage research efficiently currently considering potential use commerciallike study evaluate whole EMIFPlatformfrom Catalogue private remote research environmentprior end EMIF project order expedite research efficiency also identified bottleneck research process need addressed well technology supporting research via EMIFPlatform Prioritizing Publications D Since meeting May EMIFPLAT community ha working publication project look forward fact th consortium meeting include discussion member submission relevant journals excerpt extensive  Working Inclusively E considerable work prior official end EMIF project fiveyear mark need work inclusively progress sustainable element continue beyond IMIfunded phase excited upcoming consortium meeting celebrate work achieved shepherd project successful conclusion solidify plan sustain EMIFPlatform future content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation EMIF NEWSLETTER MAY  May  Use button jump article issue Subscribe Newsletter please complete  MAY   Shining Yet Light Impact European Medical Information Framework Project Theres old joke go something like this policeman came across man hand knee street light late night doing sir said policeman man replied lost car key looking them continued search policeman replied Ill give hand Whereabouts think dropped them response man said alley there think policeman rubbed jaw said Well searching then man retorted Well light is KEY POINTS European Medical Information Framework EMIF wa formed liberate insight evidence real world data Europe Collectively brought together remarkably diverse research development effort within EMIF address key challenge modern healthcare EMIF ha done much grow community platforms infrastructures case enabling reuse data Europe CONTRIBUTORS PROF SIR SIMON LOVESTONEProfessor Translational Neuroscience Oxford University Overall joint program lead EMIF BART VANNIEUWENHUYSESenior Director Janssen Clinical Innovation Patient Data Research JCIPDR Coordinator overall EMIF project Bringing Light Needed space need look answer pressing question medicine today alley lamppost EMIF wa formed bring light needed wanted shed light potential key liberating insight evidence real world data Europe transformation taking place healthcare becoming truly datadriven sector clinical care RD Compared many industry society healthcare ha latecomer digital realm However last five six year since EMIF wa first imagined healthcare truly moving digital realm project ha contributed change newsletterthe last IMI projectwe bringing together view around EMIF project achieved wa challenge lesson learned could going near future Achieve Collaboration EMIF ha complex project three components sociotechnical governance framework  two disease projects Alzheimers disease  metabolic consequence obesity  working early biomarker development Collectively brought together remarkably diverse research development effort within EMIF address key challenge modern healthcare Moreover recognised achieve collaboration working together clinical data generated potentially analysed latest opensource tools final meeting consortium public event spoke remarkable achievement EMIF involved it well challenge lesson learned covered much within newsletter doubt working scalewith increasingly large cohort collaboration data custodian internationally eventually globallyis going standard real world observational health research especially case cohort linked complementary datasets molecular imaging data used part EMIF learnt much develop nurture federated data network value indeed challenge linking observational data basic science two disease areas Importantly learning together ha transformed knowledge led productive lasting scientific collaborations Thank result EMIF contained newsletter also would want take opportunity thank involved collaborating EMIF project ha set stage new project impending IMI European Health Data Evidence Network EHDEN hope start later year Meanwhile sustainable element EMIF accessible beyond IMI phase research community EMIF already contributing infrastructure projectsproviding contributing harmonisation within example Setting New Precedents EMIF ha outstanding success evidenced one highest citation impact IMI project scientific output three domain continue reverberate many years Insights generated into instance variable progression Alzheimers disease liverrelated consequence obesity utilisation common data model harmonising diverse European data set new precedents EMIF ha done much grow community platforms infrastructures case enabling reuse data Europe look forward legacy carried forward least IMI programme initiative well EMIF continuation plans done much make EMIF success proud work done hope enjoy reading work EMIF newsletter many scientific paper come shining yet light key medical societal challenge may found MAY   Achievements Lessons Learned Opportunities Reflecting Past Five Years EMIF fiveyear EMIF project draw close EMIF topic lead reflected achievements lesson learned future opportunities topic lead would like share thought hope increasing sustainability EMIFs legacy KEY POINTS European Medical Information Framework EMIF project ha made major contribution towards promoting reuse healthcare data developing tool purpose applying tool field Alzheimers disease metabolic complication obesity EMIFs mission improve access reuse healthcare data ha accomplished large extent sustainability crucial order leverage full potential EMIF EMIF ha resulted new collaboration project lead hope continue future CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIFPLAT Janssen Pharma RD ULF SMITHProfessor University Gothenburg Public lead Metabolic topic JOHANNES STREFFERVP Head Early Clinical Neurology UCB EFPIA lead AD topic PIETER JELLE VISSERAssociate Professor Maastricht University VU University Medical Center Public lead AD topic DAWN WATERWORTHDirector Genetics Cardiovascular Metabolic Dermatology GSK EFPIA lead Metabolic topic Achievements Made Possible EMIF Nigel Hughes EFPIA Coordinator  say EMIF created community disparate diverse stakeholder common goal around realworld observational research stakeholder fostered scientific technical achievement project One major achievement project common information framework  link facilitate access diverse medical research data sources past five years EMIF ha created working platform mapped multiple database  representing process data standardization using OMOP Common Data Model According Johannes Streffer EFPIA lead  EMIF foster strengthens relationship among partner data providers connects research center effectively EMIFAD ha also developed tool with cohort patient selection tools tranSMART Switchbox Pieter Jelle Visser public lead EMIFAD note tool possible EMIF combination different type expertise tool pooled datasets enabled EMIFAD perform large metaanalyses fraction cost fraction time would taken otherwise EMIFAD Catalogue EFPIA lead  Dawn Waterworth say without EMIF would able access electronic medical record EMR database Europe run parallel analysis four databases also able bring together multidisciplinary team appropriate skill knowledge take advantage data would difficult otherwise According Ulf Smith public lead EMIFMetabolic scientist complementary expertise work carefully phenotyped cohort ha crucial validating importance novel biomarkers Mission Accomplished EMIF ha achieved mission developing common technical governance solution facilitating access use healthcare data EMIF helping liberate insight within Alzheimers disease metabolic disease comorbidities within project series use cases externally via Catalogue say Nigel EMIFAD Catalogue ha  registered users clearly indicating meet strong need remain challenges especially around governance provenance local data external engagement stakeholders topic lead agree sustainability essential continuing EMIFs mission leverage full potential EMIF Lessons Learned topic lead agree time spent building community within three area EMIF Platform AD Metabolic wa valuable EMIFAD topic lead happy team achieved deliverable clearly transparently created cohort infrastructures reused existing data EMIFMetabolic topic lead say project led great collaborations pleased access complementary expertise large cohort disease outcome data future similar projects topic lead aspirations One key building federated data network real world observational research Europe gaining understanding data source local governance provenance requirements Future project also focus stakeholders communicating opportunity possible reward partner organization data providers would allow better utilization access data infrastructure longterm project like EMIF topic lead would advise EFPIA partner hire people specifically work project make sure time available it Beyond EMIF topic lead agree EMIF project resulted new highlevel collaboration hope continue beyond fiveyear span project EMIFPlatform wa collaboration around OMOP common data model Within EMIFAD wa linkage between example IMI EPAD DPUK et al well wider Alzheimers research community EMIFMetabolic collaboration number EFPIA academic participant continue future Johannes says Collaborations within existing partnership strengthened strong driver research initiatives New partnership built hopefully develop Nigel suggests development already taking place believe EMIF cemented relationship academia industryEFPIA partners data source precompetitive state would suggest paved way forthcoming European Health Data Evidence Network EHDEN IMI project exciting see legacy EMIF action form project EHDEN MAY   Bridging Europe First Annual OHDSI Symposium Participants March  OHDSI Symposium Rotterdam Netherlands wearing jacket OHDSI Europe logo March    European OHDSI chapter hosted first annual OHDSI symposium theme Bridging Europe Well  people attended meeting  attending OHDSI event first time representing  different countries Many attendee several speaker directly involved EMIF meeting took place Erasmus Medical Center Rotterdam Netherlands Participants successfully contributed expanding already vibrant European Union EU OHDSI community KEY POINTS  participant attended first annual European Observational Health Data Sciences Informatics OHDSI symposium hosted Rotterdam Netherlands EU OHDSI chapter first day symposium presenter spoke adoption Observational Medical Outcomes Partnership OMOP common data model CDM need EU OHDSI initiative importance OHDSI tools more second day symposium two workshop gave participant handson experience OMOP CDM OHDSI tools CONTRIBUTORS JELLE PRAETPhDLife Science consultant CMAST bvba subcontractor Janssen Pharmaceutica PETER RIJNBEEK PhDAssistant Professor Erasmus University Medical Center Importance OMOP CDM George Hripcsak Vivian Beaumont Allen Professor Chair Biomedical Informatics Columbia University Medical Center Director Medical Information Services NewYorkPresbyterian Hospital wa first speaker day presented worldwide journey OHDSI adoption Observational Medical Outcomes Partnership OMOP CDM Currently  million patient  billion patient record mapped OMOP CDM Among user large institute like FDA eMERGE NIH IMI Peter Rijnbeek Assistant Professor Department Medical Informatics Erasmus MC Rotterdam elaborated need EU OHDSI initiative many different database structure coding system Europe healthcare system differ considerably across EU countries Harmonization OMOP CDM critical generation real world evidence fast reproducible way current one study one script approach scalable transparent moreover expensive slow prohibitive nonexpert use EU OHDSI initiative stimulate adoption OMOP CDM Europe providing platform European collaboration improve CDM vocabulary European setting Patrick Ryan Sr Director Head Epidemiology Analytics Janssen RD Adjunct Assistant Professor Biomedical Informatics Columbia University gave last talk first session last talk first session wa given Patrick Ryan Sr Director Head Epidemiology Analytics Janssen RD Adjunct Assistant Professor Biomedical Informatics Columbia University want science reproducible others even harder able repeat results said Patrick want science become reproducible need ensure every step along research process identical exactly OMOP CDM OHDSI tool important product community working together define community standard tools share evidence define best practices Adoption OMOP CDM coffee break different case adoption OMOP CDM shown Nigel Hughes Scientific director JCI Patient Data Research Janssen Belgium presented upcoming IMI European Health Data Evidence Network EHDEN project ha set goal mapping  million health record across EU OMOP CDM next five years goal ambitious Nigel Hughes expressed confidence could reach it EHDEN blank canvas build ha already developed project like example EMIF Martin Sedlmayr Professor Institute Medical Informatics Biometry TU Dresden Germany presented Medical Informatics Research Care University Medicine MIRACUM consortium Martin Sedlmayr Professor Institute Medical Informatics Biometry TU Dresden Germany introduced MIRACUM consortium Recently launched supported German government MIRACUM consortium currently represents quarter German university hospitals aim stimulate reuse data adopting OMOP CDM OHDSI tools Ben Hughes Senior Vice President RealWorld  Analytics Solutions IQVIA discussed IQVIA formerly Quintiles IMS continuously investing OMOP CDM IQVIA help many largescale institution such FDA  answer simple complex question drug safety adverseevent reporting more Following trial  database harmonized OMOP CDM IQVIA convinced OMOPs huge potential help better research IQVIA also remains realistic associated cost time requirements Rae Woong Park Professor Ajou University School Medicine South Korea presented journey South Korea successfully adopted OMOP CDM currently many participating hospital South Korea total  million patients Despite effort Professor Park promoting Korean OHDSI initiative took  month first hospital expressed interest joining Korean OHDSI initiative change came May  due Korean National Health Insurance system started using OMOP CDM story learn need get EU payer regulator board supporting EU OHDSI initiative want successful Epidemiological Presentations Daniel Prieto Associate Professor NIHR Clinician Scientist Oxford University UK introduced work group Oxford showing audience epidemiological work using patient record help study risk benefit medical devices Erica Voss Associate Director Epidemiology Analytics Janssen RD US gave overview type research done Janssen epidemiology analytics explained realworld data used conduct clinical trial feasibility studies design trial use real world data validate trial feasible need tweaking mentioned adoption OMOP CDM ha required substantial investment time money ha strong return invest get it Sir Simon Lovestone Professor Translational Neuroscience Oxford University UK spoke UKCRIS system hold data  million mental health patients data mental health patient written long text pose tremendous challenge harmonizing data Currently UKCRIS implementing consent recontact model  patient agreed contacted again tremendously speed clinical trials OMOP CDM Tools Action lunch wa time several demonstration tool related OMOP CDM  research posters demonstration included patientlevel prediction package R research network platform new features tool  latter wa presented Jos Lus Oliveira Associate Professor University Aveiro Vice Director Institute Electronics Informatics Engineering Aveiro showed audience complete EMIF Catalogue pipeline discovery assessment way reuse health data Prof Dr Jos Lus Oliveira gave realtime demonstration EMIF Catalogue online platform integrates enables discovery reuse heterogeneous biomedical databases Regulatory Considerations panel discussion Jim Slattery Senior Statistician European Medicines Agency mentioned regulator use observational data guide decision making Christian Reich Vice President Real World insights IQVIA stated lack reproducible research base decision problem company institution government solve own matter rich are asked OHDSI community make sure compliant new EU General Data Protection Regulation GDPR Michel van Speybroeck Director Data Sciences Janssen Belgium replied exact interpretation GDPR debatable new rule regulation might interpreted differently different levels However OHDSI approach use federated data network versus centralized much easier compliant new GDPR Peter Rijnbeek Assistant Professor Department Medical Informatics Erasmus MC Rotterdam closed first day symposium hilarious show closure past OHDSI symposium US including singing section greatly appreciated participants Handson Experience OHDSI Tools second day conference hosted two workshops allowing participant get handson experience OMOP CDM OHDSI tools end day participant better understanding detail OMOP CDM structure Standardized Vocabularies used harmonize data tool ecosystem OHDSI community wa also shown strong focus ATLAS tool allows browsing vocabularies defining cohorts estimating risk effects making patientlevel predictions more Information information OMOP CDM OHDSI community stay date next edition symposium please visit  MAY   Achievements Challenges Five Year IMI Project Final EMIF General Assembly Meeting Public Symposium  people attended EMIF public symposium April  discus learn European health data ecosystem April    EMIF project held final general assembly meeting Hotel Bloom Brussels Belgium BE project wa launched five year prior addition public symposium Liberating Evidence European Health Data wa hosted April  KEY POINTS European Medical Information Framework EMIF project held final general assembly meeting public symposium Brussels Belgium April    meeting participant reflected research area Alzheimers disease metabolic complication obesity well sharing poster demonstrating tool created EMIF Discussions legacy sustainability led insight may helpful future IMI projects CONTRIBUTORS JELLE PRAETPhDLife Science consultant CMAST bvba subcontractor Janssen Pharmaceutica Journey Thus Far general assembly meeting commenced Bart Vannieuwenhuyse Janssen BE Prof Sir Simon Lovestone University Oxford UK reflecting successful journey thus far EMIF wa first conceived  Since then EMIF ha lived ambition providing enabling access unprecedented volume healthcare data well accelerating research field Alzheimers disease AD metabolic complication obesity Nigel Hughes Janssen BE Johan van der Lei Erasmus MC NL reflected social technical evolution EMIF project lifetime One major challenge EMIF ha fact fly plane building it said Nigel Part success EMIF stem three topic together one overarching project also introduced challenges defining common goal across three topic academic EFPIA partners major legacy EMIF development EMIF platform associated tools well introduction CDM Europe AD Metabolic Successes Johannes Streffer UCB BE PieterJelle Visser Maastricht University NL explained ha focused heavily reuse enrichment AD cohort data turn delivered new insight pathophysiology AD helped identify potential new AD biomarkers Exemplars focused effort AD cohort catalogue enriched EMIF Biomarker discovery cohort establishment two new cohort extreme phenotype AD asked would differently redo project Johannes PieterJelle replied political legal dimension working real world data overlooked instead tackled soon possible future projects Ulf Smith University Gothenburg Sweden Dawn Waterworth GSK US stated project structure three different topic ha also critical success  wa shared interest EMIFAD study link dementia insulin resistance kind research wa possible due collaboration EMIFPlatform Working together ha enabled u identify mannose new marker insulin resistance answer critical question risk factor link progression nonalcoholic fatty liver disease NAFLD cardiovascular disease CVD heart failure Dawn Waterworth GSK US presented journey geneticist working field real world data Poster Prizes Tool Demonstrations first day ended poster session addition  posters also three realtime demonstration tool developed EMIF Myriam Alexander formerly GSK UK took home jury poster prize public poster prize wa awarded Stephen Carter University Manchester UK Cohort Research second day general assembly meeting started session work undertaken relates using cohortrelated data Isabelle Bos Maastricht University NL Sarah Westwood University Oxford UK presented outcome cerebrospinal fluid CSF analysis proteomic analysis done context multimodal biomarker discovery study Anouk den Braber Vrije Universiteit Amsterdam NL presented result EMIF  study PreclinAD study two cohort focussing extreme phenotype AD Claudia Langenberg University Cambridge UK Luca Lotta University Cambridge UK presented work using cohort data advance type  diabetes biomarkers mere association causal relationship Naveed Sattar University Glasgow UK introduced audience GlasVEGAs study metabolic reaction Europeans South Asian men compared quickly gaining enforced weight Michel van Speybroek Janssen BE Rudi Verbeeck Janssen BE explained performed harmonisation AD cohort datasets minimal dataset hosted tranSMART platform update wa also given AD cohort explorer associated AD Switchbox developed make AD cohort data available wider research community Upcoming White Paper break wa interactive workshop moderated Caroline Sage CMAST bvba BE workshop asked participant reflect experienced EMIF lesson learned outcome workshop combined result earlier survey conducted within EMIF published white paper interactive workshop people split eight different groups asked reflect experienced EMIF field continue evolve year come EHR Research lunch wa session outlining use electronic health record EHR data Naveed Sattar University Glasgow UK presented result study investigated risk developing cardiovascular disease NAFLD patients William Alazawi Queen Mary University London UK showed u gap diagnosis disease assessment NAFLD literature EHR databases Prof Sir Simon Lovestone University Oxford UK explained group ha studying link dementia inflammation specifically effect antiinflammatory drug methotrexate Rob Stewart Kings College London UK showed u work using EHR data study dementia prevalence vascular risk factor dementia Jos Lus Oliveira University Aveiro Portugal guided u many different aspect user profiles database plugins Jerboa ACHILLES community plugins TASKA ATLAS Glen James GSK UK told u experience using EMIF Catalogue answer actual research questions Peter Rijnbeek Erasmus MC NL presented Jerboa Reloaded tool wa developed within EMIF Thereafter switched gear explained work done OMOP CDM addition reported back successful OHDSI meeting Rotterdam March kickoff EU OHDSI chapter Peter Rijnbeek Erasmus MC NL holding microphone QA session project besides EMIF helping share European health data ecosystem Legacy Scenario last session day Nigel Hughes presented legacy scenario EMIF followed panel discussion sustainability EMIF Panelists included Bart Vannieuwenhuyse Prof Sir Simon Lovestone PieterJelle Visser Johannes Streffer Johan van der Lei Dawn Waterworth Katrina Loomis Pfizer US many IMI projects moving towards sustainable entity ha proven difficult general sentiment wa difficulty wa largely due many different stakeholder involved rather technological problem Lastly upcoming IMI project European Health Data  Evidence Network EHDEN wa oftenrecurring topic throughout discussion EHDEN considered heir EMIF thus big part EMIF legacy WellAttended Public Symposium Wednesday April   participant attended EMIF public symposium Liberating Evidence European Health Data day started introduction EMIF Bart Vannieuwenhuyse Prof Sir Simon Lovestone Thereafter respective topic lead gave highlevel overview tool technology developed EMIF Nigel Hughes new disease insight gained field AD Johannes Streffer metabolic complication obesity Dawn Waterworth Left Bart Vannieuwenhuyse Janssen Belgium gave audience warm welcome April  started public symposium giving highlevel introduction EMIF project Perfect Storm next session focused project currently impacting European health data ecosystem Peter Rijnbeek discussed OMOP CDM revolutionize way healthcare data used Europe allow generation evidence observational data fast reproducible manner Peter remarked perfect storm upcoming IMI project EHDEN help tremendously widespread adoption OMOP CDM throughout Europe Next Nemanja Vaci University Oxford UK presented IMI ROADMAP project try develop efficient us real world evidence benefit AD patients Adil Mardinoglu Chalmers Sweden showed audience example large biological database help solve fundamental research question better understand disease pathologies last speaker session Gerald Luscan Pfizer FR gave gave overview IMI EPAD project building platform accelerate clinical trial participant recruited EPAD Register Perspectives Privacy lunch Valentina Strammiello European Patient Forum BE gave patient perspective reuse healthcare data Interestingly patient genuinely concerned data security privacy issues want bona fide researcher able access data Patients want involved control data Thereafter Nikolaus Forgo University Vienna Austria gave audience crash course upcoming general data protection regulation GDPR effective May   Unfortunately GDPR hopedfor revolution simplify European legislation data protection penalty might higher breach GDPR GDPR also offer relief opportunity allow use real world data research purposes Next wa panel discussion Past Present Future European Health Data Ecosystem Panelists included Valentina Strammiello Nikolaus Forgo Isabelle Bos Adil Mardinoglu Thomas Allvin EFPIA BE Daniel PrietoAlhambra Oxford University UK Many interesting topic discussed as consent better Whats risk research real world data keep sharing data GDPR effective good enough job sharing outcome data research participants Projecting Forward last session projected forward looking future health data ecosystem Bo Saxberg DDO Strategic Services US gave lecture evolving value real world data augmenting currently available real world datasets eg via inclusion longitudinal trajectories tremendously increase value proposal dataset stakeholders Pierre Meulien IMI BE talked current challenge working healthcare data mentioned IMI hope address challenge future focusing inclusion stakeholders agile scalable also sustainable collaborating IMIs associated partner key initiatives full meeting report slide public symposium please visit  MAY   Liberating Evidence European Real World Data Odyssey EMIF Legacy Leaves overview EMIF Catalogue community contained therein time writing six week left prior official end IMI project known EMIF  EMIF ha one complex IMI project date incorporating three project one  technology governance framework  Alzheimers disease  metabolic consequence obesity EMIF considerable aspiration vision wa first conceived circa  European health data research domain wa different world then time took project agreed upon IMI initiated implemented saw remarkable change world ha moved digital realm including healthcare KEY POINTS EMIFAD EMIFMET contributed significantly understanding natural history Alzheimers disease metabolic consequence obesity well identifying potential biomarkers EMIFPLAT ha developed modular architecture support identification assessment reuse health data conjunction overarching governance research process EMIF platform continue beyond IMI project led Erasmus MC Rotterdam support Synapse Research Management Partners Barcelona European Health Data  Evidence Network EHDEN ambitious followup EMIF anticipated take place   CONTRIBUTORS NIGEL HUGHESEFPIA Coordinator EMIFPLAT Janssen Pharmaceutica RD One Cited Projects IMIs History EMIFAD EMIFMET contributed significantly understanding natural history respective disease areas well identifying potential biomarkers EMIF ha become one cited project IMIs history publication forthcoming Project lead EMIFAD EMIFMET concluded work especially regard interaction large datasets cohorts population data could accomplished following traditional route outside EMIF Insights research process real world data come exploring diverse use cases examining EMIFs ability respond research question within two domains evaluating platform architecture Work completed part EMIF ha also highlighted bottleneck research process well potential sociotechnical responses Meanwhile EMIFPLAT ha collaborated partner data custodian develop modular architecture support identification assessment reuse health data conjunction overarching governance research process went live publicly accessible resource January  approximately  researcher utilize Catalogue day house number data communities including population data source derived electronic health record EMIF EHR AD cohort    vaccinerelated  pediatric  Additional data community formed researcher granted access community Community Manager specific community interest accessibility continue beyond IMI project EMIF Research Process EMIF Platform wa developed considerable work multiple partner EMIF University Aveiro led architecture development Erasmus MC Rotterdam led data harmonization EMIF platform support research process query hypothesis cataloguedriven data source evaluation protocol development task management data extraction analytical output private remote research environment local governance provenance data custodian protected within federated network processing tool distributed data source instead moving data central processing hub visualization tools documents SOP process involved EMIF research process part OHDSI global collaboration EMIF ha also taken lead promoting utilizing OMOP CDM well assisting launch EU Chapter OHDSI OMOP CDM ha played critical role within EMIF making possible researcher data custodian collaborate harmonize data Ambitious FollowUp EMIF platform based collaboration EHR data custodian cohort owner EMIFAD continue beyond IMI project platform continue support open science open source collaboration researcher data custodians network network data sources continued collaboration led Erasmus MC Rotterdam support Synapse Research Management Partners Barcelona EMIF platform also provide sociotechnical input future projects including European Health Data  Evidence Network EHDEN EHDEN ambitious followup EMIF currently progressing grant process IMI anticipated start end  five years EHDEN could proposed without foundation provided EMIF diagram showing flow information EHDEN Learn look forward promoting EMIF legacy remainder project beyond Anyone wishing consider conducting research via EMIF access find module EMIF platform well instructional material information conducting research EMIF please contact  content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation EMIF WHITE PAPER SEPTEMBER  EMIF Public Symposium Liberating Evidence European Health Data Wednesday  September    Since Innovative Medicines Initiative IMI began  ha funded many successful programme improve healthcare across European Union EU European Medical Information Framework EMIF ha exception accomplishment made EMIFespecially area dementia metabolic disorders data harmonization produced proven model collaboration data management medical research so EMIF allowing research happen speed scale wa previously possible say Bart Vannieuwenhuyse CoCoordinator overall EMIF project Senior Director Janssen Clinical Innovation Patient Data Research JCIPDR content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept Toggle navigation CONTACT Fields asterisk  required First name Last name  Institution  Company Country Email  Enquiry  content Copyright EMIF right Reserved Last update  site us cookies continuing browse site agreeing use them Accept